BRITESMILE INC Form 10-K April 14, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-K

[X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended: December 28, 2002

[] TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 1-11064

BRITESMILE, INC.

(Exact name of registrant as specified in its charter)

UTAH 87-0410364

State or other jurisdiction (IRS employer of incorporation or organization) identification no.)

490 North Wiget Lane
Walnut Creek, California 94598

(Address of principal executive offices) (Zip Code)

(925) 941-6260

(Issuer's telephone number, including area code)

Securities registered pursuant to

Section 12(b) of the Act:

Name of each exchange on which registered:

None

None

Not Applicable

Securities registered pursuant to Section 12(g) of the Act:
-----common stock, par value \$0.001

Check whether the issuer (1) filed all reports required to be filed by Section 13 or $15\,\text{(d)}$ of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-K contained in this form, and no disclosure will be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. []

Indicate by checkmark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12B-2)

Yes	No	X

The aggregate market value of the registrant's common stock held by non-affiliates as of March 12, 2003 was approximately \$6,875,347 based on the closing sale price of the issuer's stock as reported by the NASDAQ SmallCap Market on such date.

The number of shares of common stock, less treasury shares, of the registrant outstanding as of March 12, 2003 was 2,428,539.

1

BRITESMILE, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

PART	I.	
Item	1.	Business3
Item	2.	Properties9
Item	3.	Legal Proceedings9
Item	4.	Submission of Matters to a Vote of Security Holders12
PART	II.	
Item	5.	Market for Registrant's Common Equity and Related Stockholder Matters
Item	6.	Selected Financial Data15
Item	7.	Management's Discussion and Analysis of Financial Condition and Results of Operations
Item	8.	Financial Statements and Supplementary Data
Item	9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
PART	III	
Item	10.	Directors and Executive Officers of the Registrant30
Item	11.	Executive Compensation
Item	12.	Security Ownership of Certain Beneficial Owners and Management37
Item	13.	Certain Relationships and Related Transactions40
Item	14.	Controls and Procedures42
PART	TV.	

Item	15.	Exhibits,	Financial	Statement	Schedules,	and Reports	on Form	n 8-K42
Signa	atur	es						48
Certi	ifica	ations						49

2

THIS ANNUAL REPORT ON FORM 10-K CONTAINS, IN ADDITION TO HISTORICAL INFORMATION, FORWARD-LOOKING STATEMENTS THAT INVOLVE SUBSTANTIAL RISKS AND UNCERTANTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THE RESULTS ANTICIPATED BY THE COMPANY AND DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES ARE DISCUSSED BELOW IN THE SECTION ENTITLED "FORWARD-LOOKING STATEMENTS" AND ELSEWHERE IN THIS ANNUAL REPORT. THE FOLLOWING DISCUSSION SHOULD BE READ TOGETHER WITH OUR FINANCIAL STATEMENTS AND RELATED NOTES THERETO INCLUDED ELSEWHERE IN THIS DOCUMENT.

During the fourth quarter of Fiscal 2002, the Company announced a 15 to 1 reverse stock split, which took effect January 27, 2003. All references in this Report to numbers of the Company's shares and to share prices herein have been adjusted for the 15 to 1 reverse stock split.

During the fourth quarter of the Company's fiscal year ended April 1, 2000, the Company adopted a 52/53-week (4 week - 4 week - 5 week quarter) fiscal calendar. In addition, the Company changed its year-end from March to December. Data in this Report reflects the consolidated results of the Company for the audited 52 week period ended December 28, 2002 ("Fiscal 2002") and December 29, 2001 ("Fiscal 2001"), the audited 39 week transition periods ended December 30, 2000 (the "Transition Period"), and the unaudited 52 week period ended December 30, 2000 ("Fiscal 2000").

PART I.

ITEM 1. BUSINESS

Introduction

BriteSmile, Inc., a Utah corporation (the "Company" or "BriteSmile"), and its affiliates develop, produce, sell and lease advanced teeth whitening products, services and technology. BriteSmile's operations include the development of technologically advanced teeth whitening processes that are distributed in professional salon-like settings dedicated solely to providing the Company's teeth whitening services and products and which are known as BriteSmile Professional Teeth Whitening Centers ("Centers"), and also in existing independent dental offices known as BriteSmile Professional Teeth Whitening Associated Centers ("Associated Centers").

BriteSmile offers consumers a new, simple and safe way to return teeth to their optimal natural whiteness in just one visit to a BriteSmile Center or BriteSmile Associated Center. The BriteSmile teeth whitening system utilizes a combination of proprietary gas plasma light or LED technology and wavelength specific gel. The unique fiber optic delivery arm of the BriteSmile device permits blue-green light to reach all 16 front teeth simultaneously, whitening the teeth by activating the wavelength specific gel, which is applied to the teeth during three consecutive twenty-minute sessions. Including the time necessary for initial customer evaluation and consultation, prep work and clean up, the customer can complete an entire teeth whitening visit in approximately 90

minutes. The result is immediate superior teeth whitening - a clinically proven average of 8-9 shades whiter - and a patient satisfaction rate of over 98%.

BriteSmile developed its light-activated teeth whitening ("LATW") technology during the fiscal year ended March 31, 1999 ("Fiscal 1999"), and in February 1999 began placement of its BS2000 LATW system (the "BS2000") in both Centers and Associated Centers. Currently, the BS2000 is used exclusively in Centers. In November 1999, BriteSmile introduced its mobile BS3000 LATW keycard system ("BS3000") into Associated Centers, and in May 2001, commenced shipping to Associated Centers its state-of-the-art BS3000PB LATW system (the "BS3000PB"), representing the latest refinements to the mobile LATW device used in Associated Centers. The BS3000 and BS3000PB can be installed more quickly than the BS2000 and provide the flexibility and mobility required in dental offices. A dentist at an Associated Center activates the BS3000 device by inserting a key card, which has been programmed to allow the device to perform the number of whitening procedures, purchased by the Associated Center. The Company ships key cards to an Associated Center after receiving a key card order via phone or fax or over the Internet. The BS3000PB device incorporates a code number system, which enables the dentist to program the device with a numerical code to perform whitening procedures based upon the number of such procedures purchased from

3

the Company. The Company provides the Associated Center dentist with the code numbers to program the BS3000PB via fax or e-mail, thus, eliminating the need to ship key cards to Associated Centers. The Company is continuing its research and development efforts to improve its current LATW systems in order to maintain and strengthen its competitive advantage.

Centers are located in major metropolitan areas nationwide. Centers offer customers a salon-like environment dedicated solely to teeth whitening and are staffed by licensed dentists and trained dental assistants. Alternatively, consumers can visit an Associated Center, where a local dentist supervises the BriteSmile procedure in his or her dental office.

As of December 28, 2002, BriteSmile had 14 Centers operating in the following locations: Beverly Hills, Irvine, Walnut Creek, Palo Alto and La Jolla, CA; Chicago, IL; Phoenix, AZ; Boca Raton, FL; Honolulu, HI; Atlanta, GA; Houston, TX; Denver, CO; Boston, MA; and New York, NY. The Centers serve as the anchor in 12 major U.S. markets, with the geographically contiguous Associated Centers providing consumers with multiple location options. This "cluster" of Associated Centers surrounding a BriteSmile Center allows the Company to have maximum advertising impact and visibility in a market by leveraging marketing and advertising dollars, and optimizing consumer exposure to the BriteSmile brand.

As of December 28, 2002, BriteSmile has contracted with dentists to operate approximately 4,636 Associated Centers throughout the United States and around the world in 67 countries. BriteSmile plans to open additional Associated Centers in the United States and in select foreign locations in the future.

The Company also sells BriteSmile brand post-whitening maintenance products, including toothpaste, mouthwash, whitening chewing gum and electric toothbrushes, to consumers in Centers, Associated Centers, and on its Internet site. The Company is currently developing other BriteSmile brand post-whitening products.

The Company operates in one reportable segment, that of teeth whitening services and products. The Company's chief operating decision-maker has determined the operating segment based upon how the business is managed and operated.

Recent Business Developments Associated Center Expansion

BriteSmile continues to identify and recruit dentists practicing in both Center and non-Center markets to establish complementary Associated Centers in their respective markets. To date, BriteSmile has contracted with dentists to operate approximately 4,636 Associated Centers as of December 28, 2002. This compares to 3,959 Associated Centers in operation at the same time last year.

International Expansion

In May 1999, the Company established BriteSmile International Limited ("BriteSmile International"), a Dublin, Ireland-based subsidiary, to facilitate international distribution of the Company's LATW systems. BriteSmile International has since introduced the BS3000 and BS3000PB in 67 countries under distributorship agreements. As of December 28, 2002, the Company has contracted with dentists to operate 1,315 Associated Centers outside the United States. BriteSmile International is continuing to explore additional international distribution opportunities in Europe, Latin America and Asia. In Fiscal 2002, International revenue was 12.7% of total revenue.

November 2002 Sale of Convertible Notes

On November 20, 2002, the Company sold to two investors in a private placement 2% convertible notes that are due and payable on November 20, 2005 (the "November 2002 Notes"). The November 2002 Notes are convertible into shares of common stock of the Company at a conversion rate of \$6.00 per share. The two investors who purchased the November 2002 Notes, both affiliates of the Company, are: LCO Investments Limited (\$2,500,000) and Bradford G. Peters (\$1,000,000). The CEO of the Company has agreed to fund an additional \$500,000 in 2003 under the same terms. LCO Investments Limited is the Company's major shareholder. LCO is a wholly owned subsidiary of the ERSE Trust. CAP Advisers Limited is a

4

co-trustee of the ERSE Trust. Mr. Pilaro, a director of the Company, is Chairman of CAP. John L. Reed is a shareholder, the Chief Executive Officer, and a director of the Company. Brad Peters is a shareholder and a director of the Company.

EVL Lease Agreement

On December 29, 2000, as amended in February 2001, March 2002, September 2002 and January 2003, the Company secured a lease line of credit of up to \$15 million from Excimer Vision Leasing L.P. ("EVL"). Anthony Pilaro, the Company's Chairman, serves as Chairman of EVL.

In addition to providing working capital to the Company, the lease line of credit enabled the Company to place up to 1,755 new BS3000PB teeth whitening devices in Associated Centers in the U.S. Pursuant to the lease line agreement, EVL purchased from the Company 1,245 BS3000 teeth-whitening devices currently used in various Associated Centers in the United States for \$5 million and immediately leased the assets back to the company. EVL leases all devices to the Company for a term of five years. The Company pays EVL a monthly rental for each device consisting of a fixed amount, plus a "variable rent" payment in the amount of \$25 for each right to perform a procedure purchased by the Associated Center where the corresponding device is located. During Fiscal 2002 and Fiscal 2001, \$2,150,000 and \$2,680,000 respectively in rent expense was recorded

relative to this lease arrangement. During Fiscal 2001, the Company utilized the remaining \$10 million available on the lease line to purchase BS 3000PB devices for placement in Associated Centers.

On March 8, 2002, the Company and EVL amended their lease agreement to provide that the variable rent portion of the monthly rental payments during 2002, in the amount of \$25 for each BriteSmile procedure, will be deferred and paid to EVL in twelve equal monthly installments beginning January 9, 2003, with interest payable on the deferred amount at a rate equal to LIBOR as quoted by The Bank of Nova Scotia for the applicable adjustment dates for deposits in U.S. Dollars for one month maturities, plus 200 basis points.

On September 18, 2002, the Company and EVL further amended their lease agreement to provide that all variable rent payments during 2002, in the amount of \$25 for each BriteSmile procedure, will be deferred and paid to EVL on January 1, 2004, with interest payable on the deferred amount at a rate equal to LIBOR as quoted by The Bank of Nova Scotia for the applicable adjustment dates for deposits in U.S. Dollars for one month maturities, plus 200 basis points. All interest having accrued on Total Deferred 2002 Variable Rent was to be paid on January 9, 2003. Thereafter, accrued interest on account of Total Deferred 2002 Variable Rent was to continue to be payable on the 9th day of each month through December 9, 2003 and on January 1, 2004.

On January 1, 2003, the Company and EVL again amended their lease agreement to provide that the variable rent portion of the monthly payment due for payments during both 2002 and 2003, in the amount of \$25 for each BriteSmile procedure, will be deferred and paid to EVL on January 1, 2004, with interest payable on the deferred amount at a rate equal to LIBOR as quoted by The Bank of Nova Scotia for the applicable adjustment dates for deposits in U.S. Dollars for one month maturities, plus 200 basis points. All such interest that accrued from March 12, 2002 to January 8, 2003 on account of the Total Deferred 2002 Variable Rent was paid on January 9, 2003. Thereafter such accrued interest on account of Total Deferred 2002 Variable Rent will continue to be payable on the 9th day of each month through December 9, 2003 and on January 1, 2004. All such interest that accrues on account of Total Deferred 2003 Variable Rent will be paid on the 9th day of each month commencing April 9, 2003 through December 9, 2003 and on January 1, 2004. In the event the Company is unable to meet its obligation to EVL on January 1, 2004, EVL has agreed to renegotiate a new repayment schedule, which would be mutually acceptable to both parties.

CAP Advisers Line of Credit

In December 2001, as amended in March 2002, July 2002 and January 2003 BriteSmile International entered into Credit and Security Agreements (the "Credit Agreements") with CAP Advisers Limited ("CAP Advisers"). The Credit Agreements provide for secured loans to the Company of up to \$5 million with an additional \$1.5 million for capital equipment. Any principal advanced under the line of credit bears interest at a fluctuating rate equal to LIBOR plus 200 basis points, payable monthly. Advances under the \$5 million portion of the line may be used for general business purposes. Mr. Pilaro, the Company's Chairman, is also Chairman of CAP Advisers. CAP Advisers is the sole trustee of the ERSE

5

Trust. The ERSE Trust owns 100% of LCO, the Company's major shareholder. As of December 28, 2002, the outstanding balance on the line of credit was \$4.7 million.

CAP Advisers Center Loan

In April 2003, the Company's Audit Committee and it's Board of Directors approved a term sheet from CAP Advisers for a \$2.5 million Center Loan (the "2003 Center Loan") to be used for capital expenditures and other specific revenue generating initiatives to be agreed and defined by BriteSmile and Cap Advisers and up to \$800,000 for general working capital. Interest is fixed at 6%, payable monthly, with Cap Advisers having the right to reset the interest rate to 200bps over 1 year LIBOR after giving BriteSmile 30 days notice. A variable fee payment of \$25 per procedure performed on the existing 127 Center chairs will commence on May 11, 2006, and continue until May 10, 2011. Variable fees will be payable 40 days after the end of the month in which the procedures are performed, except for fees due for April/May 2011 which will become payable on the maturity date. On an annualized basis the first \$500,000 of variable fees will be applied to the principal such that the \$2.5M will be fully repaid over 5 years commencing May 11, 2006. Variable payments in excess of the annual amortization of \$500,000 are deemed additional interest to Cap Advisers.

Market for Products and Services

The Company continues to believe that the market for teeth whitening services and products is large and growing. According to a study conducted by Dental Products Report, it is estimated that professionally administered bleaching products and services exceeded \$1.3 billion for the year 2000, the last year data is available. Indications are that this number has increased significantly, consistent with a proliferation of products and services available professionally. The retail market for whitening products also continues to grow, including whitening toothpastes, over-the-counter and direct-to-consumer home gel and tray systems, as well as strips.

Domestically, various independent surveys have indicated 70%-80% of adults are not happy with the current color of their teeth. This, combined with the increasing desire for physical self-improvement and a continuing rise in "vanity" spending, creates a favorable marketplace for continued long-term growth, despite the recent economic downturn. Globally, acceptance of teeth whitening and western trends in physical self-improvement continue to be encouraging. This perception is supported by the Company's continued growth in distribution as well as international Associated Center productivity, despite minimal advertising investment.

No customer accounted for more than 10% of net sales during Fiscal 2002, Fiscal 2001 or the Transition Period.

Marketing and Distribution

BriteSmile's teeth-whitening procedures are marketed primarily via consumer advertising, a somewhat unique approach within professional dentistry. The Company employs a strategy of marketing whereby all advertising includes a toll-free number for consumers to call to make an appointment at Associated Centers or at a Company-owned Center after seeing or hearing the ads. Core advertising efforts include TV, radio and print. Historically, the Company purchased most of its media locally in markets of significant density, and specifically where Centers are located. However, as the Company achieved national distribution and associated economies of scale, it switched to national advertising in the fourth quarter of 2001.

The Company built its internal infrastructure to provide the finest consumer experience in teeth whitening. In February 1999, BriteSmile established a national Call Center in order to efficiently handle incoming consumer inquiries and to book appointments via the Company's proprietary web-based scheduling system (the "Scheduler"). The Call Center, located at the Company's corporate headquarters in Walnut Creek, California, is equipped with advanced telephone and computer equipment to service consumers calling BriteSmile's toll free

telephone numbers. The Scheduler is a custom-developed software solution capable of tracking incoming calls as well as customer appointments, treatments performed in Centers, and payments. The Scheduler allows the Call Center, and each BriteSmile Center and BriteSmile Associated Center, to view and interact on a real-time basis with dentists' schedules. It also enables management to closely monitor performance of advertising campaigns and sales agents, and Center and Associated Center operational and financial results.

6

Competition

The Company's LATW procedure competes with all teeth whitening products and services. These include in-office bleaching systems, professionally administered take home bleaching systems, and over-the-counter and direct to consumer products such as pastes, gels and strips. Competition continues to proliferate, as consumer demand for whitening increases.

Numerous manufacturers and individual brands compete in the various product arenas. Recently, a number of companies have entered the LATW arena with products of their own. Some of these companies are also in the professional tray business. A significant development in 2001 was the launch of Crest WhiteStrips, a new methodology for at-home whitening. These strips are sold over-the-counter as well as in dentist's offices. Many competing products have a substantially longer treatment time (weeks or more) than the BriteSmile 1 hour procedure plus preparation time.

Virtually all professional whitening systems use some type of peroxide, usually a hydrogen peroxide for in-office procedures, and a milder carbamide peroxide for at-home use. BriteSmile's LATW system uses a 15% hydrogen peroxide solution, a relatively low percentage for an in-office procedure. As a result, BriteSmile's process has low sensitivity (less than 10%) relative to many competing procedures.

BriteSmile has performed numerous independent clinical studies on safety and efficacy. These include studies at the University of Medicine and Dentistry of New Jersey, Forsyth Institute, Loma Linda University, and New York University. These studies have not only proven the safety of the BriteSmile process on teeth, gums and dental work, but have also proven the efficacy of BriteSmile's LATW. In one of these studies BriteSmile's efficacy was compared against a leading professional take home tray system, an in-office curing-light process, and a leading whitening toothpaste. In all instances BriteSmile was proven to have significantly greater whitening efficacy as measured by the Vita-Pan(R) shade differential scale.

BriteSmile continues to invest in research and development, and is investigating advanced gel and light technology to ensure a continued leadership position in teeth whitening safety, speed and efficacy, however there is no guarantee that this leadership position will be maintained despite these efforts.

Sources of Supply

The Company has subcontracted the manufacturing of LATW devices with a single manufacturer, Peak Industries in Longmont, Colorado. The Company leases a significant number of its LATW systems used in Associated Centers from EVL pursuant to the \$15 million lease line of credit entered into on December 29, 2000. See Item 1--"Business, Recent Business Developments, EVL Lease Agreement," above. Goods purchased to produce the LATW device and gel and equip the Centers

and Associated Centers are in some cases unique and purchased from a single vendor. In those cases the Company believes it could purchase items meeting its design specifications from other vendors within the industry. Overall, the Company believes it has access to sufficient quantities of goods and materials at competitive prices to enable it to operate effectively.

Contractual Relationships with Centers

A licensed dentist, and a dental hygienist or licensed dental assistant, administer the Company's LATW process at BriteSmile Centers. Regarding the relationship between the Company and such dentists, the dentists generally create a professional corporation (the "PC"), which enters into various agreements with the Company. Pursuant to such agreements, the licensed dentist has exclusive authority regarding dental matters, including administering of the LATW. A Deficit Funding Agreement between the Company and the PC obligates the Company to fund any Center operating losses by lending necessary funds to the PC which are repayable solely from the assets of the PC, and without recourse against any officer, director, or shareholder of the PC. Under a Security Agreement between the Company and the PC, the PC grants to the Company a security interest in all of the PC's accounts, general intangibles, equipment, and fixtures to secure the PC's obligations under the Deficit Funding Agreement. Pursuant to a Management Agreement between the Company and the PC, the Company

7

manages the business and marketing aspects of the Center including providing furnishings, equipment, advertising and office space, and maintaining, repairing, and replacing furnishings as necessary.

Organizational Structure of Associated Centers

Associated Centers are located within existing independent dental offices pursuant to a BriteSmile Systems Agreement (the "Systems Agreement") between the Company and a dentist (the "Associated Center Dentist"). The Systems Agreement specifies the number of devices to be located at the Associated Center, payment terms, and the obligations of both parties with respect to use and maintenance of the LATW equipment.

Patents, Trademarks and Licenses

The Company has filed a number of patent applications related to the LATW system which have been issued or are pending, including patent applications related to the composition of the Company's whitening gel, methods of whitening teeth with light tissue isolation barriers, the Company's business method and the Company's unique system of delivery of light to all teeth simultaneously through the Company's gas-plasma light activating device. In addition, the Company has ongoing research and development efforts to improve and expand the Company's current technology, and to develop new tooth whitening compositions and light devices.

As of April 7, 2003, over ten U.S. patents have issued to the Company relating to methods of LATW, compositions for use in LATW, an adjustable articulated positioning device, a portable, high power arc lamp system, and a design for a device that provides light to teeth for whitening procedures. Similar patent applications have issued or are pending in various countries including the European Union, Canada, Japan, and Australia.

Although the Company intends to continue to apply for patents as advised by patent counsel, there can be no assurance that such patents will be issued or

that, when they are issued, they will not be infringed upon by third parties or that they will cover all aspects of the product or system to which they relate. Management generally believes that the Company's success depends more on its ability to maintain state-of-the-art technology and to market its products on a price-competitive and value-added basis, than on any legal protection that patents may provide. The Company relies, and will continue to rely, on trade secrets, know-how and other unpatented proprietary information in its business. Certain key employees and consultants of the Company are required to enter into confidentiality and/or non-competition agreements to protect the confidential information of the Company. However, there is no assurance that these agreements would be enforceable if they are breached or, if enforced, that they would adequately protect the Company or provide an adequate remedy for the damage that may be caused by such a breach.

The Company owns the rights to the registered trademarks and service marks in the U.S. and in several foreign countries including but not limited to "BriteSmile" (name and logo), "BriteSmile Professional Teeth Whitening Centers," and "BriteSmile Associated Teeth Whitening Center."

Government Regulation

The Company's business operations are subject to certain federal, state and local statutes, regulations and ordinances (collectively, "government regulations"), including those governing health and safety. The LATW system is categorized as a Class 1 Medical Device as defined by the Food and Drug Administration ("FDA"). The LATW device is utilized specifically to perform cosmetic dental procedures (teeth whitening); as such, the Company's LATW device is not subject to the customary rules, regulations and oversight by the FDA. There can be no assurance that some or all of the existing government regulations will not change significantly or adversely in the future, or that the Company will not become subject to compliance with additional and stricter government regulations.

In most states the Company's teeth whitening procedure is deemed to be a part of the practice of dentistry. Generally, states impose licensing and other requirements on the practice of dentistry. In addition, some states prohibit general business corporations (such as the Company) from engaging in the practice of dentistry. In some states the BriteSmile corporate structure and contractual relationships with PCs that provide LATW services to consumers must be reviewed by, and require the express approval of, that state's agency governing the practice of dentistry (such as a Board of Dental Examiners). In those states, approval is necessary for the Company's operation of Centers.

8

The Company has obtained all required government approvals for its Centers. The Company intends to continue to cooperate with state regulatory agencies, and obtain all necessary governmental approvals. Even with such approvals there can be no assurance that future enactments, amendments, or interpretations of government regulations will not be more stringent, and will not require structural, organizational, and operational modifications of the Company's existing and future contractual relationships with PCs which provide LATW services. However, management believes that its present and contemplated operation of Centers is and will be in compliance in all material respects with applicable federal, state and local regulations.

The Company regularly monitors developments in government regulations relating to the practice of dentistry. The Company plans to structure all of its agreements, operations and marketing in accordance with applicable government

regulations, although there can be no assurance that its arrangements will not be successfully challenged or that required changes may not have a material adverse effect on the Company's operations or profitability.

Product Liability

The Company may become subject from time to time to suits alleging negligence, product liability or related causes of action, although no such action is currently pending. The Company maintains product liability insurance coverage for its products and services with coverage limits of \$5 million per occurrence and \$5 million per year. While the Company intends to continue to insure against such actions, there can be no assurance that the Company will be successful in maintaining such coverage or that the limits of such policies will be adequate or renewable at prices or on terms that are sufficient for the Company's business. A successful claim against the Company in excess of any insurance coverage could have a material adverse effect upon the Company and its financial condition. Claims against the Company, regardless of the merit or eventual outcome of such claims, also may have a material adverse effect on the Company's reputation and business.

Employees

As of March 1, 2003, the Company had 123 full-time employees and 14 part-time employees. None of the Company's employees are represented by a union and the Company is not aware of any efforts to unionize any employees. The Company believes its labor relations are satisfactory.

ITEM 2. DESCRIPTION OF PROPERTY

The Company leases its 13,746 square foot corporate office facility in Walnut Creek, California. The lease agreement runs through April 2007. This facility is used for administration, Call Center and office space. In July 2001, the Company entered into a lease agreement through July 2003 for a 10,255 square foot facility for warehousing and distribution located in Walnut Creek, California next to its corporate office. The Company is currently negotiating an extension of that lease.

As of the date of this Report, the Company has fourteen Centers operating under lease agreements expiring starting December 2003 through January 2010.

Each Center lease covers prime street-level retail spaces, consisting of approximately 1,800-5,200 square feet, with improvements to create attractive salon settings. Equipment available at each Center includes BriteSmile LATW devices, dental chairs and dental cabinetry and equipment, all in excellent condition.

During fiscal year 2001 the Company closed three of its less productive Centers. In December 2001, the Company also terminated plans to open a new Center in San Francisco. At present, the Company remains obligated under these leases through 2010, and has sub-leased and/or negotiated termination of the leases.

ITEM 3. LEGAL PROCEEDINGS

BriteSmile, Inc. v. Discus Dental, Inc. and Salim Nathoo, filed in the United States District Court for the Northern District of California. The Company filed an initial complaint against Discus Dental, Inc. ("Discus"), Culver City, California, on July 8, 2002, asserting claims of infringement of the Company's U.S. Patents No. 6,343,933, issued February 5, 2002, and U.S. Patent No.

6,361,320, issued March 26, 2002. On February 28, 2003, the Company amended its existing lawsuit against Discus by adding Salim Nathoo ("Nathoo") as a defendant. The complaint, civil action number 3:C02-CV-03220 JSW, as amended, further alleges misappropriation of the Company's trade secrets, civil conspiracy, and unfair competition and business practices by Discuss and Nathoo; breach of contract and breach of fiduciary duty by Mr. Nathoo, and tortuous interference with contract by Discus. The complaint alleges that Nathoo and Discus conspired to misappropriate BriteSmile's trade secrets in violation of Nathoo's contractual obligations to the Company. The amended lawsuit alleges that, as BriteSmile's Medical Director, Nathoo had and continues to have, an obligation to keep BriteSmile's trade secrets confidential. Beginning in 2001, Discus Dental and Nathoo entered into an agreement whereby Discus Dental paid Nathoo at least \$2.5 million over a less than two year period for Nathoo's "consulting" services, which included paying Nathoo to share with Discus the Company's trade secrets. The lawsuit alleges further that in, December 2002, a third party informed BriteSmile of Nathoo's activities, and that when confronted by BriteSmile, Nathoo admitted to receiving \$2.5 million from Discus. The Company seeks a permanent injunction against both Discus and Nathoo to prevent further infringement of its patents and improper disclosure of the Company's trade secrets, lost profits, treble damages and attorneys fees for willful patent infringement, punitive damages, and other relief. On March 25, 2003, Discus filed its Answer to the Amended Complaint and Counterclaims. In its Answer, Discus denies any liability for BriteSmile's claims. Discuss also raises affirmative defenses, including claims that its products and processes do not infringe BriteSmile's patents, and that BriteSmile's patents are invalid and unenforceable. Discus asserts counterclaims against BriteSmile, seeking (i) judicial declarations that BriteSmile's patents are invalid, unenforceable, and have not been infringed, (ii) tortuous interference with prospective economic advantage and economic business relations, and (iii) unfair competition. Discus asks for declarations that its products and processes do not violate BriteSmile's patents, that BriteSmile's patents are unenforceable, that BriteSmile has no protectable trade secrets, that BriteSmile's contracts with dentists which contain contractual restrictions on the purchase and use of competitive systems are unenforceable and should be enjoined, lost profits, treble damages and attorneys fees.

Salim Nathoo v. BriteSmile Leasing. On March 6, 2003, Nathoo filed a lawsuit against BriteSmile Leasing, a subsidiary of the Company in the New Jersey state court. In this action, Nathoo alleges that the Company breached its agreement to pay Nathoo money, and that such failure should result in the reversion of certain patent rights, which were previously assigned by Nathoo to the Company, back to Nathoo. Nathoo also seeks the payment of profits derived from the patent rights. As of March 31, 2003, counsel for the Company is preparing to answer the complaint.

Smile Inc. Asia Pte. Ltd. v. BriteSmile. On April 23, 2002, Smile Inc. Asia Pte. Ltd. ("Smile") sued the Company and BriteSmile Management, Inc., a wholly owned subsidiary of the Company, in the Third Judicial District Court in Salt Lake City, Utah. The Complaint alleges that BriteSmile Management breached its 1998 distributor agreement with Smile by failing to fill orders placed and to perform other obligations under the agreement. The Complaint also alleges that BriteSmile Management and the Company fraudulently induced Smile to enter into the distributor agreement, and includes claims for damages based on alleged unjust enrichment, civil conspiracy, breach of the duty of good faith and fair dealing, interference with contractual and economic relations, and fraudulent transfer. The Company believes that the claims asserted by Smile are entirely without merit and will vigorously defend the lawsuit. The Company has commenced discovery with regard to Smile's claims.

BriteSmile v. Discus Dental, filed in Contra Costa County Superior Court, California. On May 31, 2002, the Company filed a complaint against Discus Dental, Inc. in Contra Costa County Superior Court, California, case no. C02-01611, alleging causes of action for Intentional Interference with Contractual Relationship, Negligent Interference with Contractual Relationship, Violation of Unfair Business Practice Act - Loss Leader, Violation of Unfair Business Practice Act, Trade Libel and Injunctive Relief. The complaint alleges that Discus Dental and other defendants yet to be identified wrongfully interfered with the Company's contractual relationships with its Associated Center dentists, in part by writing letters with the purpose of inducing the Company's Associated Dentists to terminate their contracts with the Company and switch to Discus' Zoom! system, and by making false and disparaging statements concerning the Company's system. The Complaint seeks damages for loss of business, punitive damages, injunctive relief, and costs of suit. On June 27, 2002, Discus filed a demurrer to the Company's complaint, challenging the legal sufficiency of the complaint. On June 30, 2002, the court ruled that the Company

10

will be able to pursue its claims as alleged in the complaint except for the second cause of action alleging Negligent Interference with Contractual Relationship. This case was stayed on March 11, 2003 and will remain stayed until a status conference scheduled for September 2003.

11

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On December 24, 2002, the Company asked shareholders of approximately 62% of the common stock of the Company to sign written consents to effect a reverse stock split for the Company's common stock, which they did. The result was that fifteen shares of common stock before the effective date of the reverse split would become one share after the effective date. Because more than a majority of the shareholders approved this transaction, a vote of all of the shareholders was not necessary under Utah law. Pursuant to the consents signed by certain shareholders, the split became effective January 27, 2003. The Company paid the costs of soliciting certain shareholders for their consent and for printing and mailing information statements associated therewith.

PART II.

ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

On April 7, 2000, the common stock of the Company commenced trading on the NASDAQ National Market System under the symbol "BSML". Prior to its listing on NASDAQ, from 1995 to April 2000, the Company's common stock was listed for trading on the American Stock Exchange (AMEX: BWT). The following table sets forth, for each full quarterly period during Fiscal 2002 and Fiscal 2001, high and low sales price information (adjusted for 15 to 1 reverse split) as reported by NASDAQ or other electronic services, as the case may be.

	High	Low
Fiscal Year Ended December 28, 2002 December 28, 2002 September 28, 2002 June 29, 2002 March 30, 2002	\$ 14.100 \$ 31.800 \$ 89.700 \$ 93.900	\$ 4.500 \$ 12.000 \$ 28.650 \$ 60.000
Fiscal Year Ended December 29, 2001		
December 29, 2001	\$ 93.750	\$ 48.990
September 29, 2001	\$217.500	\$ 78.045
June 30, 2001	\$180.000	\$ 74.070
March 31, 2001	\$ 93.750	\$ 36.570

As of December 28, 2002, there were 298 holders of record of the Company's common stock. This number excludes any estimate by the Company of the number of beneficial owners of shares held in street name, the accuracy of which cannot be quaranteed.

Dividends

The Company has not paid any cash dividends on its common stock since its inception. The policy of the Board of Directors is to retain earnings to support growth; therefore, the Company does not anticipate paying any cash dividends on its common stock in the foreseeable future.

Recent Sales of Unregistered Securities

In addition to the issuance of shares upon exercise of options or otherwise as reported elsewhere in this Report, within the past three years the Company has issued securities in transactions summarized below without registration of the securities under the Securities Act of 1933, as amended (the "1933 Act").

Fiscal Year Ending April 1, 2000

Effective January 12, 2000, the Company sold 5,155 shares of restricted common stock in a private placement to Andrew J. McKelvey for cash proceeds of

12

\$464,000, or \$90.00 per share. Mr. McKelvey also acquired certain registration rights with respect to the shares. Bradford Peters, a director of the Company, shares in the economic benefits of any appreciation in the shares acquired by Mr. McKelvey. Mr. Peters also shares with Mr. McKelvey authority to dispose of the shares.

Effective January 12, 2000, the Company sold in a private placement a total of 2,062 shares of restricted common stock to Quota Rabbicco II, Ltd., Argonaut Partnership, L.P., and David E. Gerstenhaber for \$186,000 or \$90.00 per share. The three purchasers also acquired certain registration rights with respect to the shares.

On January 18, 2000, the Company sold in a private placement 222,222 shares of its restricted common stock, representing 14.2 percent of the Company's total shares then outstanding, for aggregate proceeds of \$20 million. The purchase price was \$90.00 per share. The shares were issued to three private investors, Pequot Private Equity Fund II, L.P. (111,111 shares), Pequot Partners Fund, L.P. (55,556 shares), and Pequot International Fund, Inc. (55,555

shares) (collectively, the "Pequot Investors"). Pursuant to a Registration Rights Agreement entered into with the Company, the Pequot Investors acquired both demand and piggyback registration rights to cause the Company to register their shares for offer and sale under the 1933 Act. Pursuant to a Voting and Co-Sale Agreement entered into between the Company, the Pequot Investors, and LCO, the Company granted to the Pequot Investors the right to designate one person to be appointed to the Board of Directors of the Company, and to be nominated for election as a director in any shareholders meeting at which directors are elected. The Pequot Investors appointed Mr. Gerald Poch to serve as their designee on the Company's Board of Directors.

Transition Period Ended December 30, 2000

On June 29 and August 3, 2000, the Company sold to eleven investors (the "Note Investors") in a private placement its 5% Subordinated Convertible Notes due June 29, 2005 (the "August 2000 Notes") in the aggregate principal amount of \$20 million.

Initially, the August 2000 Notes were convertible into shares of the Company's restricted common stock at a per share conversion price of \$92.70, which was 120% of the average of the closing bid price of the common stock during the ten-day trading period immediately prior to June 27, 2000, the date the transaction documents were signed. The Company also issued to the Investors, pro rata, warrants (the "Warrants") for the purchase a total of 107,875 shares of common stock, which have a term of five years and initially had an exercise price of \$108.15 per share. The fair value of the Warrants issued of \$2.1 million was recorded as a discount against the August 2000 Notes and was being amortized over the life of the August 2000 Notes to interest expense.

Pursuant to Registration Rights Agreements between the Note Investors and the Company, the Company registered with the SEC, effective August 25, 2000, the shares of common stock underlying the August 2000 Notes and Warrants for resale under the Securities Act.

Seven of the Note Investors, who purchased an aggregate amount of \$15.7 million of the August 2000 Notes, are affiliates of the Company. The affiliated Note Investors include LCO (the principal shareholder of the Company and affiliated with director Anthony Pilaro), John Reed (shareholder, CEO and director), Dr. Gasper Lazzara, Jr. (director), Andrew McKelvey (shareholder and affiliated with director Bradford Peters), and Pequot Private Equity Fund II, L.P., Pequot International Fund, Inc., and the Pequot Investors (shareholders and affiliated with director Gerald Poch).

Four of the Note Investors, who purchased a total of \$4.3\$ million principal amount of the August 2000 Notes, are unaffiliated with the Company.

On December 5, 2000, the Company sold to LCO in a private placement a Convertible Promissory Note (the "December 2000 Note") in the aggregate principal amount of \$5 million. This December 2000 Note, together with accrued interest of \$132,644, was converted into 68,435 shares of restricted common stock of the Company on April 10, 2001, at a conversion price of \$75.00 per share. In conjunction with the issuance of the December 2000 Note, LCO was granted warrants for 16,667 shares at \$75.00 per share. The fair value of the warrants issued of \$253,000 was recorded as a discount against the December 2000 Note and is being amortized over the life of the December 2000 Note to interest expense. The unamortized fair value of the warrants was recorded as additional interest expense upon conversion of the Note. All 16,667 warrants granted in

connection with the December 2000 Note Offering remain outstanding and unexercised.

As a result of the issuance of the December 2000 Note, the conversion price of the August 2000 Notes, and the exercise price of the Warrants, was automatically adjusted to \$75.00 per share. Additionally, the fair value of the Warrants was adjusted to \$2.3 million based upon the change in conversion price and the discount of the August 2000 Notes was adjusted accordingly. The new fair value of the Warrants was amortized on a straight-line basis over the life of the August 2000 Notes to interest expense.

In December 2000, LCO, the Company's principal shareholder, and John Reed, the Company's Chief Executive Officer, converted \$5.6 million of their August 2000 Notes, together with accrued interest, into an aggregate of 74,822 shares of common stock. This conversion was effected at the \$75.00 conversion price.

Subsequently, effective December 14, 2000, other Note Investors agreed with the Company to convert an aggregate of \$13,642,000 in principal amount of their August 2000 Notes, together with accrued interest, into 237,904 shares of common stock at an amended conversion price of \$57.938 per share.

Of the original principal amount of \$20 million of the August 2000 Notes, \$800,000 in principal amount remains outstanding at December 28, 2002.

Of the original Warrants issued in the August 2000 Note offering, all 100,421 warrants remain outstanding and unexercised.

The conversion price of the remaining August 2000 Notes, and the exercise price of the Warrants, continues to be subject to additional adjustments from time to time upon the occurrence of certain other events described in the August 2000 Notes and Warrants, including future issuances of common stock for consideration less than the conversion price then in effect, stock splits or reverse stock splits, and the occurrence of certain major corporate events such as mergers, sale of assets, tender offers or exchange offers. At any time after the third anniversary of the issuance date of the August 2000 Notes, the remaining Note holders have the right, but not the obligation, to cause the Company to redeem all or a portion of the August 2000 Notes.

Fiscal Year Ended December 29, 2001

On April 30, 2001, the Company completed a private offering (the "Offering") of its restricted common stock, par value \$0.001 per share ("common stock"). The Offering involved sales of a total of 358,095 Shares to 17 accredited investors and their affiliated funds (the "April 2001 Investors"). None of the April 2001 Investors were affiliated with the Company before the completion of the Offering. The Company sold the Shares for \$78.75 per share, yielding gross proceeds to the Company of \$28.2 million.

In connection with the Offering, the Company paid the Placement Agent five percent of the gross proceeds of the Offering, or \$1,410,000, and issued to the Placement Agent warrants to purchase a total of 35,810 shares of restricted common stock for a per share purchase price of \$78.75. The warrants have a five-year term. The fees paid to the Placement Agent and the fair value of the warrants of \$704,000 were netted against the Offering proceeds. To date, the Placement Agent has exercised warrants to purchase 28,603 shares of common stock.

In connection with the Offering, the Company filed with the SEC a registration statement covering the Shares and the common stock underlying the warrants issued to the Placement Agent. The SEC declared the registration statement

effective on June 11, 2001.

With respect to all of the foregoing offers and sales of restricted and unregistered securities by the Company, the Company relied on the provisions of Sections 3(b) and 4(2) of the 1933 Act and rules and regulations promulgated thereunder, and upon Regulation S promulgated by the Securities and Exchange Commission, including, but not limited to Rules 505 and 506 of Regulation D, in that such transactions did not involve any public offering of securities and were exempt from registration under the 1933 Act. The offer and sale of the securities in each instance was not made by any means of general solicitation; the securities were acquired by the investors without a view toward distribution; and all purchasers represented to the Company that they were sophisticated and experienced in such transactions and investments and able

14

to bear the economic risk of their investment. A legend was placed on the certificates and instruments representing these securities stating that the securities evidenced by such certificates or instruments, as the case may be, were not registered under the 1933 Act and setting forth the restrictions on their transfer and sale. Each investor also signed a written agreement, or agreed to so sign upon exercise of their options, that the securities would not be sold without registration under the 1933 Act or pursuant to an applicable exemption from such registration.

Fiscal Year Ended December 28, 2002

On November 20, 2002, the Company sold to two investors in a private placement 2% convertible notes that are due and payable on November 20, 2005 (the "November 2002 Notes"). The November 2002 Notes are convertible into shares of common stock of the Company at a conversion rate of \$6.00 per share. The two investors who purchased the November 2002 Notes, both affiliates of the Company, are: LCO Investments Limited (\$2,500,000) and Bradford G. Peters (\$1,000,000). The CEO of the Company has agreed to fund an additional \$500,000 in 2003 under the same terms.

As of December 28, 2002, \$800,000 of the original August 2000 Notes remain outstanding. As a result of the issuance of the November 2002 Notes described above, the conversion price of these original August 2000 Notes, and the exercise price of the Warrants, was automatically adjusted to \$6.00 per share. The unamortized discount on these notes is \$51,000 as of December 28, 2002 and is being amortized over the life of the notes to interest expense.

Stock Options

Since March 31, 1998, the Company has granted options to purchase shares of common stock to employees, directors, or key consultants pursuant to the Company's 1997 Stock Option and Incentive Plan (the "1997 Plan"). As of December 28, 2002, options for 52,031 shares of common stock have been exercised, 313,794 have been forfeited and 271,936 remain outstanding and unexercised. Additional options for 110,222 shares have been granted to certain vendors, consultants and employee outside the 1997 Plan, and 47,733 shares remain outstanding and unexercised as of the date of this Report. Such vendors and consultants outside the 1997 Plan have exercised options for 38,955 shares. The exercise price of the options granted during that period ranges from \$4.95 to \$206.25 per share. Most of the options vest and become exercisable in increments over time.

In September 2002, the Company completed a voluntary stock option exchange offer for its eligible employees. Participating employees had the opportunity to

cancel previously granted options in exchange for an equal number of new options granted on March 24, 2003, that date which was six months and one day following the date on which the Company canceled the old options. As a result of this program, 150,134 options were canceled. Effective March 24, 2003, the Company granted to the employee participants in the exchange program new options under the 1997 Plan for 150,134 aggregate shares, at an exercise price of \$10.77 per share, the fair market value of the Company's common stock on that date.

The Company has registered with the SEC, on Form S-8, up to 466,667 shares of common stock subject to stock options which have been or may in the future be granted under the Company's 1997 Plan, and up to 45,000 shares of common stock subject to stock options or warrants which have been granted to consultants or advisers outside the 1997 Plan. The Company intends to register with the SEC on Form S-8 such additional shares of common stock as will be necessary to cover all 500,000 option shares presently authorized to be issued under the Company's 1997 Plan.

ITEM 6. SELECTED FINANCIAL DATA

The selected consolidated financial data set forth below with respect to the Company's consolidated statements of earnings and consolidated balance sheets for the periods indicated are derived from the consolidated financial statements of the Company. The Statement of Operations data for the year ended December 30, 2000 is derived from unaudited financial statements. The data set forth should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations," and the audited consolidated financial statements and related notes thereto.

15

	Dec 28, 2002	Dec 29, 2001	Dec 30, 2000
Consolidated Balance Sheet Data:		(in thous	ands, except per
Cash and cash equivalents	\$ 3 , 527	\$ 7 , 162	\$ 5 , 701
Working capital/(deficit)	(3,584)	1,357	(4,808)
Current assets	8,582	14,771	13,257
Total assets	31,099	39,847	30,131
Long-term obligations, less current maturities	13,332	4,120	1,727
Shareholders' equity	3 , 799	20,556	9,519

9-month Transition Period Ended

	Dec.28,	Year Ended Dec.29, 2001	Dec. 30,	Year 2 -
Consolidated Statement of Operations data:			(in thousands,	except p
Center whitening fees, net Associated center whitening fees, net Product sales	22,46	60 24,0	\$33 \$ 9,3 948 5,7 849 1,2	66
Net Sales	39 , 32	23 43,2	230 16,3	04
Operating and occupancy costs Selling, general and administrative Research and development Depreciation and amortization Restructuring expense Impairment charges Loss on sale/leaseback	34,48 92 6,09	30 43,4 23 1,8		56 11 30 78 54
Total operating expenses	56 , 4	77 68 , 8	396 54 , 8	29
Loss from operations	(17,15	54) (25,6	566) (38 , 5	25)
Other income (expense), net	(1,53	37) (7 	(5,9	61)
Loss before income tax provision Provision for income taxes		91) (26,4 30	(44, 4 57	86) 26
Net Loss, before cumulative effect of change in accounting principle Cumulative effect of change in accounting principle	\$ (18,7	71) \$ (26 , 4	99) \$ (44,5	12) \$ 72)

16

\$	(7.86)	\$	(11.85)	\$	(27.26)	\$
				\$	(0.17)	\$
\$	(7.86)	===: \$ ===:	(11.85)	\$ =====	(27.43)	\$ ====
2,	,427 , 412	2	,236,688 =======	1	,632,912 =======	1
	 \$	\$ (7.86)	\$ (7.86) \$		- \$	\$ (7.86) \$ (11.85) \$ (27.43)

17

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THIS ANNUAL REPORT ON FORM 10-K CONTAINS, IN ADDITION TO HISTORICAL INFORMATION, FORWARD-LOOKING STATEMENTS THAT INVOLVE SUBSTANTIAL RISKS AND UNCERTANTIES. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THE RESULTS ANTICIPATED BY THE COMPANY AND DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES ARE DISCUSSED BELOW IN THE SECTION ENTITLED "FORWARD-LOOKING STATEMENTS" AND ELSEWHERE IN THIS ANNUAL REPORT. THE FOLLOWING DISCUSSION SHOULD BE READ TOGETHER WITH OUR FINANCIAL STATEMENTS AND RELATED NOTES THERETO INCLUDED ELSEWHERE IN THIS DOCUMENT.

General

The Company's discussion and analysis of its financial condition and results of operations are based upon the Company's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, including those related to customer programs and incentives, bad debts, inventories, income taxes, warranty obligations, financing operations, restructuring, and contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Critical Accounting Policies And Estimates

The Company believes the following critical accounting policies affect its more significant judgments and estimates used in the preparation of its consolidated financial statements.

Revenue Recognition

BriteSmile recognizes revenue related to retail products at the time such products are sold to customers.

BriteSmile recognizes revenue at Company operated Centers at the time a whitening procedure is performed.

BriteSmile records deferred revenue at the time of sale of key cards and access codes to Associated Centers. Revenue is subsequently recognized over the period that the whitening procedures, which can be performed via the key cards and access codes, are performed, currently estimated at 30 days from the date of shipment. A material change to the estimated time period over which the key cards and access codes are used could have a significant impact on BriteSmile's revenue in the period of change as well as future periods.

BriteSmile's policy is not to accept any return of key cards or access codes during the course of the agreement with an Associated Center; however, it does provide credits to the ultimate whitening customer for a "whitening guarantee." BriteSmile recognizes those credits by reducing its revenue.

Bad Debt

BriteSmile maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. A considerable amount of judgment is required in assessing the ultimate realization of accounts receivable including the current credit-worthiness of each customer. If the financial condition of BriteSmile's customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

18

Inventory

BriteSmile is required to state its inventories at the lower of cost or market. BriteSmile writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions, as well as for damaged goods. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required.

Property, Equipment and Improvements - Carrying Value Near Recoverability Estimate

BriteSmile evaluates its property, equipment and improvements for impairment whenever indicators of impairment exist. Management determined that impairment indicators did exist in Fiscal 2001 based upon continued operating losses and negative cash flow. As a result, BriteSmile recorded an impairment charge of \$1.2 million. No impairment charge was recorded during Fiscal 2002.

Store Closures

During Fiscal 2001 and the Transition Period, BriteSmile recorded significant reserves in connection with store closures. These reserves include estimates pertaining to employee separation costs and the settlements of contractual obligations, primarily property leases. Although the Company does not anticipate significant changes, the actual costs related to the closures may differ from these estimates.

Legal Contingencies

BriteSmile is currently a party to certain legal action. Management does not believe that current pending litigation will have a material adverse effect on BriteSmile's consolidated financial position. This conclusion has been developed in consultation with outside counsel handling BriteSmile's representation in these matters. It is possible, however, that future results of operations for any particular quarterly or annual period could be materially affected by changes in management's assumptions and the effectiveness of BriteSmile's strategies related to these legal actions.

BriteSmile recognizes the costs of legal services in the periods incurred.

Results of Operations

The following are explanations of significant period-to-date changes for Fiscal 2002 compared to Fiscal 2001:

Revenues

Total Revenues, net. Total revenues, net decreased by \$3.9 million, or 9.0%, to \$39.3 million for Fiscal 2002, from \$43.2 million for Fiscal 2001.

Center Whitening Fees, net. Center whitening fees, net decreased by \$1.6 million or 11.2%, to \$12.7 million for Fiscal 2002, from \$14.3 million for Fiscal 2001. This was attributable to an 8.8% decrease in comparable store procedures. The number of procedures performed in the Centers decreased 10.7% to 28,699 procedures for Fiscal 2002, compared to 32,136 Center procedures in Fiscal 2001.

Associated Center Whitening Fees, net. Associated Center whitening fees, net decreased by \$1.6 million, or 6.6%, to \$22.5 million for Fiscal 2002, from \$24.1 million for Fiscal 2001. This decrease was primarily due to the decrease in procedures in Domestic Associated Centers. The decrease in revenue was partially offset by an increase in International Associated Center procedures and revenues. The number of procedures sold to both domestic and international Associated Centers increased 6.8% to 127,450 procedures in Fiscal 2002 compared to 119,380 procedures in Fiscal 2001. The Company pays third party distributors in connection with sales of procedures to international associated centers. For that reason, international revenue is less than domestic revenue.

Although the Company does not believe that its business follows seasonal trends, it has recognized that at various times during the months of July and August and again during December and January, a substantial number of Associated Center

19

Dentists (both domestic and international) shut down their practices for vacation. As a result, the frequency of key card and access code purchases by Associated Centers during these months can decline as well.

The Company continues to execute its strategic plan of expanding distribution into the professional dental practice channel through its Associated Centers. The Company opened 586 new associated centers, net of terminations in Fiscal 2002. Additionally, the Company anticipates opening additional Associated Centers in domestic and international locations over the next twelve months. There can be no guarantee that the Company will be successful in executing its business plan.

Product Sales. Product sales decreased by \$700,000, or 14.6%, to \$4.1 million for Fiscal 2002, from \$4.8 million for Fiscal 2001. Product sales represent the Company's toothpaste, mouthwash, whitening gum and Sonicare toothbrush products sold at Centers, Associated Centers, and through its website. Product sales are expected to increase during the next twelve months as a result of the introduction of additional oral care products to be sold at Centers, Associated Centers, and through the Company's Internet website.

Operating Costs and Expenses

Operating and Occupancy Costs. Operating and occupancy costs decreased as a percentage of sales to 37% for a total of \$14.7 million for Fiscal 2002, from 39% for a total of \$16.7 million for Fiscal 2001. This decrease as a percentage of sales is a reflection of lower sales and other reduced operating expenses.

Selling, General and Administrative Expenses. Selling, general and administrative expenses decreased as a percentage of sales to 88% for Fiscal 2002 compared to 101% in Fiscal 2001. In dollar terms, total selling, general and administrative expenses decreased \$9.0 million to \$34.5 million for Fiscal 2002 compared to \$43.5 million for Fiscal 2001. This decrease was primarily attributable to the expense restructuring that was initiated at the start of the fourth quarter of 2001. Offset by \$265,000 in stock option compensation expense, discussed in Note 10. The Company was able to streamline its field personnel, which resulted in lower corporate overhead expenses.

Research and Development Expenses. Research and development expenses decreased as both a percentage of sales and in dollar terms to \$923,000, or 2% of sales, for Fiscal 2002, compared to \$1.8 million or 4% of sales, in Fiscal 2001. Research and development costs incurred during Fiscal 2002 represent expenses related to safety and efficacy studies along with various other research studies to expand the Company's leadership position in the teeth-whitening industry.

Depreciation and Amortization. Depreciation and amortization increased as a percentage of sales to 16%, or \$6.1 million for Fiscal 2002 compared to 11% of sales, or \$4.7 million in Fiscal 2001. This percentage increase, as well as, the increase in total depreciation dollars is due to the greater number of BS3000 and BS3000PB systems deployed in the Associated Centers.

Restructuring Expense. In Fiscal 2002, the Company revised its estimate of the Restructuring expense and took a charge of \$304,000. Restructuring expense for Fiscal 2001 was \$879,000. In December 2001, the Company's Board of Directors and management decided to terminate the construction of a Center in San Francisco, California as a result of the economic downturn and the concentrated effect of the failure of numerous "Dot-Com" businesses in Northern California. As a result of the Company's decision to cease construction on this Center, the Company reserved \$987,000 for lease liability obligations. This amount was offset by a reduction of the Fiscal 2000 restructuring liability of \$108,000.

Impairment Charge. The Company recognized no impairment charge in Fiscal 2002. In Fiscal 2001, the Company recognized a \$1.2 million non-cash charge for impairment of assets related to the aborted construction of the San Francisco Center, as leasehold improvements were not deemed recoverable. See Restructuring Expense above.

Interest Expense. Interest expense increased \$520,000 to \$1.6 million for Fiscal 2002 from \$1.1 million for Fiscal 2001. The increase is due to an increase in expense related to the issuance of warrants as well as an increase in borrowing.

Interest Income. Interest income decreased \$241,000 to \$66,000 in Fiscal 2002 from \$307,000 in Fiscal 2001, as a result of lower average cash balances.

The following are explanations of significant period-to-date changes for Fiscal 2001 and the Company's 52 weeks ended December 30, 2000 ("Fiscal 2000"):

Revenues

Total Revenues, net. Total revenues, net increased by \$23.5 million, or 119%, to \$43.2 million for Fiscal 2001, from \$19.7 million for Fiscal 2000.

Center Whitening Fees, net. Center whitening fees, net increased by \$3 million or 27%, to \$14.3 million for Fiscal 2001, from \$11.3 million for Fiscal 2000. This increase was attributable to a 21% comparable store increase for eleven of the fourteen Centers. The increase can also be attributed to the fact that three of the Centers were in operation for only a portion of Fiscal 2000, but operated for the full 12 months in Fiscal 2001. This overall increase was partially offset by the closure of three underperforming Centers in the first quarter of Fiscal 2001 that were open throughout 2000. The number of procedures performed in the Centers increased 23% to 32,136 procedures for Fiscal 2001, compared to 26,197 Center procedures in Fiscal 2000.

Associated Center Whitening Fees, net. Associated Center whitening fees, net increased by \$17.0 million, or 243%, to \$24.0 million for Fiscal 2001, from \$7.0 million for Fiscal 2000. This increase was primarily due to the operation of 3,959 Associated Centers at the end of Fiscal 2001 compared to just 1,155 Associated Centers that were in operation at the end of Fiscal 2000. Of the 3,959 Associated Centers in operation at December 29, 2001, 652 were international locations. The number of procedures sold to the Associated Centers increased 224% to 119,380 procedures in Fiscal 2001 compared to 36,856 procedures in Fiscal 2000.

Although the Company does not believe that its business follows seasonal trends, it has recognized that at various times during the months of July and August and again during December and January, a substantial number of Associated Center Dentists (both domestic and international) shut down their practices for vacation. As a result, the frequency of key card and access code purchases by Associated Centers during these months can decline as well.

The Company continues to execute its strategic plan of expanding distribution into the professional dental practice channel through its Associated Centers. Additionally, the Company anticipates opening additional Associated Centers in domestic and international locations over the next twelve months. There can be no guarantee that the Company will be successful in executing its business plan.

Product Sales. Product sales increased by \$3.4 million, or 243%, to \$4.8 million for Fiscal 2001, from \$1.4 million for Fiscal 2000. Product sales represent the Company's toothpaste, mouthwash, whitening gum and Sonicare toothbrush products sold at Centers, Associated Centers, and through its website. Product sales are expected to increase during the next twelve months as a result of the introduction of additional oral care products to be sold at Centers, Associated Centers, and through the Company's Internet website.

Operating Costs and Expenses

Operating and Occupancy Costs. Operating and occupancy costs decreased as a percentage of sales to 39% for a total of \$16.7 million for Fiscal 2001, from 82% for a total of \$16.6 million for Fiscal 2000. This decrease as a percentage of sales is a reflection of the lower fixed cost structure of the Associated Center sales channel and the fact that the cost structure for the 14 Centers is

essentially fixed. Also, in the first quarter of Fiscal 2001, the Company closed three under performing Centers. The total operating and occupancy costs of these three closed Centers was \$260,000 for the period they were open in Fiscal 2001, compared to total operating and occupancy costs of \$1.8 million for the same three Centers in Fiscal 2000.

Selling, General and Administrative Expenses. Selling, general and administrative expenses decreased as a percentage of sales to 101% for Fiscal 2001 compared to 163% in Fiscal 2000. In dollar terms, total selling, general and administrative expenses increased \$10.7 million to \$43.5 million for Fiscal 2001 compared to \$32.8 million for Fiscal 2000. This increase was primarily attributable to increased expenses to support the Company's extensive

21

growth in Fiscal 2001, including: (i) salaries and benefits and (ii) sales, training, marketing and advertising activities. As a result of catching up on the backlog of new customers which required higher than originally expected field personnel costs, at the start of the fourth quarter of 2001 the Company was able to streamline its field personnel which will result in lower costs in the future, as well as reductions in corporate overhead expenses.

Additionally, in Fiscal 2001 the Company recognized \$1,554,000 in non-cash compensation expense as a result of the issuance of warrants and options to outside consultants, and the revaluation of previously issued warrants.

Research and Development Expenses. Research and development expenses decreased as both a percentage of sales and in dollar terms to \$1.8 million, or 4% of sales, for Fiscal 2001, compared to \$2.3 million or 11% of sales, in Fiscal 2000. Research and development costs incurred during Fiscal 2001 represent expenses related to safety and efficacy studies along with various other research studies to expand the Company's leadership position in the teeth-whitening industry.

Depreciation and Amortization. Depreciation and amortization decreased as a percentage of sales to 11%, or \$4.7 million for Fiscal 2001 compared to 22% of sales, or \$4.5 million in Fiscal 2000. This percentage decrease is primarily due to the increase in both Center and Associated Center sales. The increase in total depreciation dollars is due to the greater number of BS3000 and BS3000PB systems deployed in the Associated Centers, offset by (i) smaller depreciation resulting from the closure of three Centers in the first quarter of Fiscal 2001, and (ii) the leasing of BS3000 and BS3000PB machines under capital leases and the resulting lower relative amortization expense.

Restructuring Expense. Restructuring expense was \$879,000 for Fiscal 2001 compared to \$950,000 for Fiscal 2000. In Fiscal 2000, the Company's Board of Directors and management decided to close its Centers in Pasadena, CA, Ft. Lauderdale, FL and Coral Gables, FL due to underperformance. The Company took an initial impairment charge of \$950,000. In December 2001, the Company's Board of Directors and management decided to terminate the construction of a Center in San Francisco, California as a result of the pending recession and the concentrated effect of the failure of numerous "Dot-Com" businesses in Northern California. As a result of the Company's decision to cease construction on this Center, the Company reserved \$987,000 for lease liability obligations. This amount was offset by a reduction of the Fiscal 2000 restructuring liability of \$108,000.

Impairment Charge. The Company recognized a \$1.2 million non-cash charge for impairment of assets related to the aborted construction of the San Francisco

Center, as leasehold improvements were not deemed recoverable. The Company incurred a similar charge of \$1.3\$ million in 2000 for three closed Centers. See Restructuring Expense above.

Interest Expense. Interest expense decreased \$4.8 million to \$1.1 million for Fiscal 2001 from \$5.9 million for Fiscal 2000. The significant decrease is due to the fact that the Company recognized \$3.4 million of interest expense related to the beneficial conversion of notes in Fiscal 2000. The \$1.1 million of interest expense is primarily comprised of interest on the EVL lease line and the EVL working capital loan, together with interest on outstanding August 2000 Notes.

Interest Income. Interest income increased \$88,000 to \$307,000 in Fiscal 2001 from \$219,000 in Fiscal 2000, as a result of higher average cash balances throughout the fiscal year.

Liquidity and Capital Resources

General

The Company's principal sources of liquidity have been proceeds from issuances of common stock and debt At December 28, 2002, the Company had \$3.5 million of cash and cash equivalents. The Company anticipates signing contracts for additional Associated Centers during the next twelve months. This expansion is contingent upon several factors, including available cash resources and acceptance by consumers and Associated Center dentists of the Company's LATW services. The Company expects that its principal uses of cash will be to provide working capital, to finance capital expenditures, and to satisfy other general corporate expenses. In particular, the Company plans to use its cash to finance its marketing strategy.

22

During the first quarter of 2002, the Company obtained a \$2.5 million line of credit from CAP Advisers, and \$4 million in shortfall guarantees. As amended in March 2002, July 2002 and January 2003, the line of credit was increased to \$6.5 million. See "CAP Advisers Line of Credit," and "Additional Working Capital Guarantees" below. The Company also amended its EVL Lease Agreement to defer payment of monthly rental on LATW devices to year 2004. See "EVL Lease Line Amendment" below.

CAP Advisers Line of Credit

In December 2001, as amended in March 2002, July 2002 and January 2003, BriteSmile International, a wholly-owned subsidiary of the Company, entered into Credit and Security Agreements with CAP Advisers which provide for a \$6.5 million line of credit facility of which, \$1.5 million is for the purchase of capital equipment. As of December 28, 2002, \$4.7 million has been drawn on the line.

EVL Lease Amendment

The Company pays EVL a monthly rental for each LATW device leased, consisting of a fixed amount, plus a "variable rent" payment in the amount of \$125 for each key card or access code sold to an Associated Center where EVL is the lessor of the LATW device. Of the 4,636 LATW devices in operation at Associated Centers at December 28, 2002, 3,000 of such devices were leased to the Company by EVL. Each

key card or access code enables Associated Center dentists to perform 5 teeth whitening procedures resulting in variable rent of \$25 per procedure.

On March 8, 2002, the Company and EVL amended their lease agreement to provide that the variable rent portion of the monthly rental payments during 2002, in the amount of \$25 for each BriteSmile procedure, will be deferred and paid to EVL in twelve equal monthly installments beginning January 9, 2003, with interest payable on the deferred amount at a rate equal to LIBOR, as quoted by The Bank of Nova Scotia for the applicable adjustment dates for deposits in U.S. Dollars for one month maturities, plus 200 basis points. A total of \$2.1 million has been deferred for the Fiscal 2002.

In September 2002 and January 2003, the Company and EVL amended their lease agreement to provide that all variable rent payments during both 2002 and 2003, in the amount of \$25 for each BriteSmile procedure, will be deferred and paid to EVL on January 1, 2004, with interest payable on the deferred amount at a rate equal to LIBOR as quoted by The Bank of Nova Scotia for the applicable adjustment dates for deposits in U.S. Dollars for one month maturities, plus 200 basis points. All such interest that accrued from March 12, 2002 to January 8, 2003 on account of the Total Deferred 2002 Variable Rent was paid on January 9, 2003. Thereafter such accrued interest on account of Total Deferred 2002 Variable Rent will continue to be payable on the 9th day of each month through December 9, 2003 and on January 1, 2004. All such interest that accrues on account of Total Deferred 2003 Variable Rent will be paid on the 9th day of each month commencing April 9, 2003 through December 9, 2003 and on January 1, 2004. In the event the Company is unable to meet its obligation to EVL on January 1, 2004, EVL has agreed to renegotiate a new repayment schedule, which would be mutually acceptable to both parties.

Additional Working Capital Guarantees

In March 2002 the Company received Commitment Letters from the Guarantors to severally purchase, on or before December 31, 2002, up to \$4 million of additional shares of common stock of the Company (or to otherwise secure, collateralize, or make available such funds to the Company). In consideration for the Guarantors' commitment, the Company issued to the Guarantors five-year warrants to purchase an aggregate of 5,333 shares of common stock of the Company at an exercise price of \$70.50 per share.

Pursuant to the Commitment Letters, on November 20, 2002, the Company sold to two investors in a private placement 2% convertible notes that are due and payable on November 20, 2005 (the "November 2002 Notes"). The November 2002 Notes are convertible into shares of common stock of the Company at a conversion rate of \$6.00 per share. The two investors, who purchased the November 2002 Notes, both affiliates of the Company, are:

23

LCO Investments Limited (\$2,500,000) and Bradford G. Peters (\$1,000,000). The CEO of the Company has agreed to fund an additional \$500,000 in 2003 under the same terms. Accordingly, as of December 28, 2002, the Company had received \$3.5 of the total \$4.0 million committed pursuant to the Commitment Letters.

To date, the Company has yet to achieve profitability. The Company does not expect to be profitable in 2003. The Company has implemented initiatives to increase sales and decrease expenses to assure its viability for the next 12 months. The Company also has developed a contingency plan in anticipation of

prolonged negative business impact resulting from the War in Iraq.

To date, the Company's principal sources of liquidity have been proceeds from issuance of common stock and debt. At December 28, 2002, the Company had \$3.5 million in cash and borrowing capacity under lines of credit totaling \$300,000.

Additionally, as discussed below, subsequent to December 28, 2002, the Company obtained the following borrowing availability:

- o \$500,000 convertible notes under the same terms as the November 2002 Notes described in Note 9.
- o \$1.5 million increase in the Credit Agreements with CAP Advisers. The increase is for the international revenue generating initiatives.
- o \$2.5 million Center Loan with CAP Advisers. This credit facility is for general working capital needs (\$800,000) and capital expenditures and specific revenue generating initiatives (\$1.7 million).

The Company believes that cash on hand along with available borrowing capacity discussed above will be sufficient to sustain operations through the end of 2003.

Payments Due By Period

Contractual Obligations	Total	Less Than 1 Year	1-3 Years	4-5 Y
Long-Term Debt	12,696	500	7,450	4,
Capital Lease Obligations	2,986	956	1,800	
Operating Leases	12,921	2,921	4,497	3,
Lease Obligation for Closed Centers	1,236	197	410	
Total Contractual Cash Obligations	29,839	4,574	14,157	8,

24

Factors that may affect our performance $% \left(1\right) =\left(1\right) +\left(1\right) +\left($

Inflation

Most of the Company's products are purchased in finished form and packaged by the supplier or at the Company's headquarters. The Company anticipates usual inflationary increases in the price of its products and does not intend to pass these increases along to its customers, primarily as a result of other operating efficiencies gained through changing the sourcing of certain of its products. In general, the Company does not believe that inflation has had a material effect on its results of operations in recent years. However, there can be no assurance that the Company's business will not be affected by inflation in the future.

Seasonality

The Company believes that its business follows seasonal trends due to the closing of some Associated Center dental offices in July and August, and again in November and December, for vacations. As a result, the Company's sales

performance could potentially be affected.

Forward Looking Statements

The statements contained in this Report that are not purely historical are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act. These statements relate to the Company's expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future. They may be identified by the use of words or phrases such as "believes," "expects," "anticipates," "should," "plans," "estimates," and "potential," among others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis of Financial Condition and Results of Operations regarding the Company's financial performance, revenue and expense levels in the future and the sufficiency of its existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The Company believes that many of the risks set forth here and in the Company's filings with the Securities and Exchange Commission are part of doing business in the industry in which the Company operates and competes and will likely be present in all periods reported. The forward-looking statements contained in this Report are made as of the date of this Report and the Company assumes no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements. Among others, risks and uncertainties that may affect the business, financial condition, performance, development, and results of operations of the Company include:

We have a limited operating history upon which to evaluate our likelihood of success.

We have only manufactured and distributed our BS2000 since November 1998, the BS3000 since November 1999 and the BS3000PB since May 2001. We opened our first Center in Walnut Creek, California in February 1999, and BriteSmile Associated Centers began performing LATW procedures in April 1999. Therefore, we have a limited relevant operating history upon which to evaluate the likelihood of our success. Investors must evaluate the likelihood of our success in light of the risks, expenses and difficulties frequently encountered in the operation and expansion of a new business and the development and marketing of new products. We cannot be certain that our business strategy will be successful or that we will successfully address these risks and difficulties. Our failure to address any of these risks or difficulties could have a material adverse effect on our business.

We have a history of losses and accumulated deficit and this trend of losses may continue in the future.

For Fiscal 2002, we had a net loss of \$19.1 million, for Fiscal 2001, we had a net loss of \$26.5 million and for the Transition Period ended December 30, 2000 we had a net loss of \$44.8 million. As of December 28, 2002, our accumulated deficit was \$135.3 million. Our ability to reach and sustain profitability will depend, in part, upon the successful marketing of our existing services and products and the successful and timely introduction of new services and products. We anticipate that net losses will continue for the foreseeable future. We can give no assurances that we will achieve profitability or, if achieved, that we will sustain profitability.

Our success will depend on acceptance of our LATW process and post-whitening maintenance products.

We derive substantially all of our revenues from our LATW procedures, a relatively new teeth-whitening concept for consumers. We also market BriteSmile brand toothpaste, electric toothbrushes, mouthwash, chewing gum and post-whitening procedure touchup kits through our Centers and Associated Centers. Our success will depend in large part on our ability to successfully encourage consumers, dentists and dental office employees to switch from traditional and less expensive bleaching tray whitening methods to our LATW system, and on our ability to successfully market our line of post-whitening maintenance products. There can be no assurance that consumers will accept our procedure or products. Typically, medical and dental insurance policies do not cover teeth whitening procedures, including the Company's LATW procedure, or whitening maintenance products, which may have an adverse impact upon the market acceptance of our products and services.

Our success will depend on our ability to update our technology to remain competitive.

The dental device and supply industry is subject to technological change. As technological changes occur in the marketplace, we may have to modify our products in order to become or remain competitive or to ensure that our products do not become obsolete. While we are continuing our research and development efforts to improve our current LATW systems in order to strengthen our competitive advantage, we cannot assure that we will successfully implement technological improvements to our LATW systems on a timely basis, or at all. If we fail to anticipate or respond in a cost-effective and timely manner to government requirements, market trends or customer demands, or if there are any significant delays in product development or introduction, our revenues and profit margins may decline which could adversely affect our cash flows, liquidity and operating results.

We may have problems financing our future growth.

Our growth strategy includes investment in and expansion of Associated Centers throughout the United States and internationally, increasing awareness of the BriteSmile brand and developing and marketing our brand name and retail products. To finance our prior growth we have sold debt and equity securities; however, additional funds are needed in the future for continued expansion. We cannot assure that additional financing will be available or that, if available, it will be on terms favorable to our stockholders or us. If needed funds are not available, we may be required to close existing Centers, and/or limit or forego the establishment of new Associated Centers and the development of new products, or limit the scope of our current operations, which could have a material adverse effect on our business, operating results and financial condition. We may be required to take other actions that may lessen the value of our common stock, including borrowing money on terms that are not favorable to us. Raising the needed funds through the sale of additional shares of our common stock or securities convertible into shares of common stock may result in dilution to current stockholders.

We are subject to competition.

The market for teeth whitening products and services is highly competitive. Competition in the market for teeth whitening products and services may intensify in the future. Numerous well-established companies and smaller entrepreneurial companies are focusing significant resources on developing and marketing products and services that will compete with our products and services. In addition, many of our current and potential competitors have greater financial, technical, operational and marketing resources. Teeth

whitening products and services offered by our competitors include traditional and often less expensive bleaching tray methods and other forms of heat or light activated curing methods. We may not be able to compete successfully against these competitors in developing, marketing and distributing our services and products, which could result in the loss of customers and could have a material adverse effect on our business. Competitive pressures may also force prices for teeth whitening services down and such price reductions may adversely affect our potential future revenue.

26

We are susceptible to product liability suits and if a lawsuit is brought against us it could result in us having to pay large legal expenses and/or judgments.

Although no lawsuits have been filed against the Company relating to our products or services, because of the nature of the dental device industry, there can be no assurance that we will not be subject to such claims in the future. Our products come into contact with vulnerable areas of the human body, such as the mouth, tongue, teeth and gums, and, therefore, the sale and support of dental products makes us susceptible to the risk of such claims. A successful product liability claim or claim arising as a result of use of our products or services brought against us, or the negative publicity brought up by such claim, could have a material adverse effect on our business. We maintain product liability insurance with coverage limits of \$5 million per occurrence and \$5 million per year. While we believe that we maintain adequate insurance coverage that is reasonable and customary for our business, we cannot assure that the amount of insurance will be adequate to satisfy claims made against us in the future, or that we will be able to obtain insurance in the future at satisfactory rates or in adequate amounts.

Future growth may place strains on our managerial, operational and financial resources and we may be unable to recruit and retain qualified personnel.

If we grow as expected, a significant strain on our managerial, operational and financial resources may occur. Further, as the number of Associated Centers, customers, advertisers and other business partners grows, we will be required to manage multiple relationships with various Center dentists, Associated Center dentists, customers, strategic partners and other third parties. Future growth or increase in the number of our strategic relationships may strain our managerial, operational and financial resources, thereby inhibiting our ability to achieve the rapid execution necessary to successfully implement our business plan. In addition, our future success will also depend on our ability to expand our sales and marketing organization and our support organization commensurate with the growth of our business.

We may experience shortages of the supplies we need because we do not have long-term agreements with suppliers.

Our success depends to a large degree on our ability to provide our affiliated dentists with our LATW systems, and a sufficient supply of teeth whitening gels and maintenance products. Since our BS2000 was first used commercially, we have relied upon manufacturing and supply agreements with multiple suppliers and a single manufacturer of our LATW systems. Effective April, 2001, the Company's LATW systems are manufactured by Peak Industries, Longmont, Colorado, pursuant to an agreement between the Company and Peak. We have no long-term purchase contracts or other contractual assurance of continued supply, pricing or access to new products. While we believe that we have good relationships with our

suppliers and our manufacturer, if we are unable to extend or secure manufacturing services or to obtain component parts or finished products from one or more key vendors on a timely basis and on acceptable commercial terms, our results of operations could be seriously harmed.

We need to successfully manage our growth in order for the addition of any new Associated Centers to be profitable.

Even though we have grown in the past two years in terms of numbers of Centers and Associated Centers opened and in operation, we may not be able to achieve profitable operations at the Centers. We currently have 14 Centers in operation. Our future growth primarily depends upon expansion of the number of our Associated Centers. We cannot assure that we will be successful in expanding the number of Associated Centers, or that such Associated Centers will achieve sales levels satisfactory to us.

BriteSmile has certain debt.

BriteSmile has \$15.3 million of debt outstanding as of December 28, 2002. The degree to which BriteSmile is leveraged could have important consequences to the shareholders, including the following:

27

- o BriteSmile's ability to obtain additional financing for working capital, capital expenditures, acquisitions or general corporate purposes may be impaired;
- o BriteSmile must pay interest on its debt, leaving less funds for other purposes;
- o BriteSmile may be at a competitive disadvantage to its less leveraged competitors; and
- o BriteSmile may be more vulnerable to a downturn in general economic conditions.

If BriteSmile were to default on its debt obligations for any reason, there can be no assurance that any assets will remain for BriteSmile's shareholders after payment of amounts owed to debt holders.

See Item 7--Management's Discussion of Financial Condition and Results of Operations, "Liquidity and Capital Resources."

BriteSmile does not intend to pay dividends.

BriteSmile does not anticipate paying any cash dividends on its common stock to its shareholders for the foreseeable future. BriteSmile intends to retain future earnings, if any, for use in the operation and expansion of its business. In addition, it is possible that any debt financing agreements entered into by BriteSmile in the future may contain restrictions on BriteSmile's ability to declare dividends.

We cannot guarantee that the patents we have applied for will be granted, or that even if granted, they will not be infringed by competitors.

The Company has an expansive and growing portfolio of patents to protect its intellectual property rights. In 2002, a number of patents relating to the LATW systems were granted, including patents covering the methods of whitening comprising of a bleaching composition exposed to light to accelerate whitening, which has been asserted in a patent lawsuit against a major competitor. The Company also has a number of patent applications related to the composition of our whitening gel, tissue isolation useful in light-activated teeth whitening, our business method and our unique system of delivery of light to all teeth simultaneously. In addition, we have ongoing research and development efforts to expand and improve our current technology, and to develop new teeth whitening compositions and light devices. Although the Company intends to continue to apply for patents as advised by patent counsel, there can be no assurance that such patents will be issued or that, when they are issued, they will not be infringed upon by third parties or that they will cover all aspects of the product or systems to which they relate.

The rights we rely upon to protect our intellectual property underlying our products and services may not be adequate, which could enable third parties to use our technology and would reduce our ability to compete in the market.

In addition to patents, we rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements and other contractual provisions and technical measures to protect our intellectual property rights. Nevertheless, these measures may not be adequate to safeguard the technology underlying our products and services. If they do not protect our rights, third parties could use our technology, and our ability to compete in the market would be reduced. In addition, employees, consultants and others who participate in the development of our products and services may breach their agreements with us regarding our intellectual property, and we may not have adequate remedies for the breach. We also may not be able to effectively protect our intellectual property rights in some foreign countries. For a variety of reasons, we may decide not to file for additional patent, copyright or trademark protection outside of the United States or in foreign jurisdictions. We also realize that our trade secrets may become known through other means not currently foreseen by us. Notwithstanding our efforts to protect our intellectual property, our competitors may independently develop similar or alternative technologies or products that are equal or superior to our technology and products without infringing on any of our intellectual property rights or design around our proprietary technologies.

Our products or services could infringe on the intellectual property rights of others, which may cause us to engage in costly litigation and, if we are not

28

successful, could also cause us to pay substantial damages and prohibit us from selling our products or services.

Third parties may assert infringement or other intellectual property claims against us. We may have to pay substantial damages, including treble damages, for past infringement if it is ultimately determined that our products or services infringe a third party's proprietary rights. Further, we may be prohibited from selling our products before we obtain a license, which, if available at all, may require us to pay substantial royalties. Even if these claims are without merit, defending a lawsuit takes significant time, may be expensive and may divert management's attention from other business concerns. Notwithstanding the foregoing, we are not aware of any infringement claims asserted against us by others.

We are subject to government regulation regarding the corporate practice of dentistry.

Our corporate structure, operation of Centers and contractual relationships with the licensed dentists at our Centers are subject to government regulation and may be reviewed by applicable state agencies governing the practice of dentistry (such as a Board of Dental Examiners). We believe that our present and contemplated operation of Centers is and will be in compliance in all material respects with applicable federal, state and local laws and regulations, and that favorable review of our corporate structure would be obtained from any state agency which chooses to review our operational structure. However, we cannot assure that such favorable review would be obtained in all instances. If we are unable to obtain favorable review, we may be subject to penalties. Further, if we are unable to comply with the applicable laws and regulations in any state, we may be limited in those states to offering our LATW procedure through Associated Centers. We continue to cooperate with state regulatory agencies to respond to any requests for information about our business structure and to obtain any necessary governmental approvals. We cannot assure that future enactments, amendments or interpretations of government regulations will not be more stringent, and will not require structural, organizational or operational modifications to our existing or future contractual relationships with the licensed dentists at our Centers who provide our services.

We may become subject to government regulation regarding our teeth whitening services and products.

The light used in the LATW systems is categorized as a Class I Medical Device as defined by the Food and Drug Administration ("FDA"). As long as the light is used specifically to perform cosmetic dental procedures (teeth whitening), it is not subject to pre-market notification requirements, although we are subject to FDA requirements regarding handling of complaints and other general FDA record keeping standards. There can be no assurance that some or all of the existing government regulations will not change significantly or adversely in the future, or that we will not become subject to compliance with additional and stricter government regulations which could, in the future, affect our revenue.

Ownership of our common stock is concentrated in a limited number of shareholders.

Current directors and executive officers of the Company, or their affiliates, own and control approximately 80% of the Company and, therefore, have ultimate authority to make all major decisions affecting our business, including the identity and make-up of the Company's Board of Directors, and any other matters requiring approval of the shareholders of the Company.

Our efforts to build strong brand identity and customer loyalty may not be successful.

We believe that establishing and maintaining brand identity and brand loyalty is critical to attracting customers, dentists and other strategic partners. In order to attract and retain these groups, and respond to competitive pressures, we intend to continue substantial spending to create and maintain brand loyalty. We believe that advertising rates, and the cost of advertising campaigns in particular, could increase substantially in the future. If our branding efforts are not successful, our results of operations could be adversely affected.

Promotion and enhancement of the BriteSmile brand will also depend on our success in consistently providing a high-quality customer experience for our teeth whitening services and satisfaction with our products. If customers do not perceive our service and product offerings to be of high quality, or if we introduce new services and products that are not favorably received by these groups, the value of the BriteSmile brand could be harmed. Any brand

29

impairment or dilution could decrease the attractiveness of BriteSmile to one or more of these groups which could harm our reputation, reduce our net revenue and cause us to lose customers.

Changes in required accounting practices may affect our reported operating results and stock price

Any future changes to applicable GAAP standards or additional SEC statements on relevant accounting policies may require us to further change our practices. These uncertainties may cause our reported operating results and stock price to decline.

Failures in our information technology systems or the systems of third parties could adversely affect our business and result in a loss of customers.

Our Company's web site or our Internet-based Scheduler system may experience slow response times, decreased capacity to accommodate a large number of customers or a temporary disruption in service for a variety of reasons. Additionally, power outages and delays in such service may interrupt or prevent us from immediately coordinating with the schedules of Centers and Associated Centers, and may interrupt or prevent customers from arranging for our services or from ordering our products through our e-Commerce Internet site. Any of these potential problems could have an adverse effect on business.

Computer hardware and software components to our Scheduler system are located at our headquarters. In addition, a back-up file server and tape back-ups of the Scheduler database reside both at our headquarters and off-site. Delays in scheduling teeth whitening procedures would result if we were required to use our backup computer hardware and software systems. Nevertheless, natural disasters such as floods, fires, and power outages, telecommunications failures, physical or electronic break-ins or vandalism, viruses and other similar events could damage our hardware and software systems, lead to a loss of data, cause substantial disruption in our business operations, and have a material adverse effect on our business.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Company's consolidated financial statements and associated notes are set forth on pages F-1 through F-32.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None

PART III.

ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT

The following sets forth the name, age and position of each director and executive officer of the Company as of the date of this Report:

NAME AGE CURRENT POSITION(S) (1) (2)

John Reed	61	Chief Executive Officer and Director
Bruce Fleming	45	President and Director
Paul Dawson	48	Chief Executive Officer of BriteSmile
		International Limited, a subsidiary of the
		Company
Derek Correia	34	Executive Vice President, Marketing
John Dong	49	Executive Vice President, Chief Financial
		Officer and Secretary

30

Stephen Miller		56	Executive Vice-President, Manufacturing and Distribution	
Anthony M. Pilaro		67	Chairman of the Board	
R. Eric Montgomery		47	Director	
Peter Schechter		43	Director	
Bradford G. Peters		35	Director	
L. Tim Pierce		51	Director	
Harry Thompson		72	Director	
Gerald Poch		56	Director	
Dr. Gasper Lazzara, J	ſr.	59	Director	

(1) All directors serve for one year and until their successors are elected and qualified. All officers serve at the pleasure of the Board of Directors. There are no family relationships between any of the officers and directors.

John L. Reed

Prior to joining the Company in June 1999 as its Chief Executive Officer, Mr. Reed was Chairman of the Pacific Retailing Division of Duty Free Shoppers Group Limited ("DFS"), the world's leading specialty retailer catering to international travelers. At DFS he was responsible for the operations of multiple retail stores, including the largest single, self-standing retail operation in the world. During his 21-year career at DFS, prior to being named Chairman of the Pacific Retail Division in 1997, Mr. Reed was President of DFS Hawaii. From 1982 to 1988, Mr. Reed was President of the DFS U.S. Mainland Operation. Mr. Reed has also served as Vice President of Merchandising for both Federated Department Stores and John Wanamaker.

Bruce Fleming

Mr. Fleming was named President and a director of the Company in June 2002. Prior to joining the Company, Mr. Fleming served as Senior Vice President Global Head of OTC for Novartis Consumer Healthcare, Inc. From 1981 through January 2001, Mr. Fleming worked with Johnson & Johnson in several capacities, including Worldwide Vice President over Consumer Oral and Wound Care Franchises for Johnson & Johnson Consumer Products Companies (November 1995 to October 1998), Worldwide Vice President - Wound Care for Johnson & Johnson Consumer Products Companies (October 1998 through April 1999), and Worldwide Vice President over Consumer Sector Business Development for Johnson & Johnson Consumer Companies, Inc. (April 1999 to January 2001). Mr. Fleming received a Master's Degree in Public and Private Management from the Yale School of Organization and Management in 1985, and an AB Degree from Harvard College in 1979.

Paul Dawson

Mr. Dawson, prior to joining the Company's subsidiary, BriteSmile International as its Chief Executive Officer, was Chief Executive Officer of Camus International, a global marketer of luxury goods. During his nine-year tenure with Camus, he spearheaded an aggressive worldwide market expansion program of the company's premium cognac market. Prior to Camus, Mr. Dawson held the position of Engagement Manager at McKinsey & Company, an international consulting firm. While at McKinsey, he advised a broad range of multinational consumer companies on international expansion strategies. Mr. Dawson has lived and worked in the United States, Europe, Asia and the Middle East. He holds masters degrees from Cambridge University and UC Berkeley, and an MBA from Stanford University.

John Dong

Mr. Dong joined the Company as acting Chief Financial Officer in September 2002 and was appointed Chief Financial Officer and Executive Vice President on December 11, 2003. For 12 of the past 15 years prior to joining BriteSmile,

31

Mr. Dong founded and grew a consulting firm specializing in acquisitions; turnarounds, IPO's and divestitures. Mr. Dong's extensive experience includes financial services, as well as broad knowledge of high tech development firms, venture capital, and high tech franchising. Prior to starting his consulting firm, Mr. Dong spent 7 years as a senior internal consultant with Wells Fargo Bank and led the IPO effort for San Francisco Federal Savings. Most recently he was the Chief Financial Officer and a Board Member of DV Capital, a diversified Venture Capital firm. Mr. Dong graduated form the University of California at Berkeley with a Bachelors Degree in Accounting and Finance. Mr. Dong also holds an MBA and earned his CPA credentials with Coopers & Lybrand, Int'l.

Derek Correia

Mr. Correia initially joined BriteSmile in September 2000. In January 2002, he was appointed Executive Vice President, Marketing. Mr. Correia brings to the Company 10 years of experience in consumer marketing and brand management working for Fortune 500 companies with dynamic consumer brands. Prior to joining BriteSmile, Mr. Correia served as Senior Vice President of Marketing for Renaissance Cruises; Vice-President, Product and Brand Marketing for Burger King Corporation; and Director, Innovation and Brand Marketing for Pizza Hut, Inc.

Stephen Miller

In October 2000, Stephen Miller was appointed Executive Vice President, Manufacturing and Distribution. Prior to joining BriteSmile in May 1999 as its Executive Vice President, Real Estate and Construction, Mr. Miller was for 11 years Vice President of Facility Development for DFS. While at DFS, Mr. Miller was responsible for the development of the flagship retail gallerias, high-end boutiques, duty free stores and entertainment complexes in the U.S., Oceania and the Pacific. Prior to DFS, Mr. Miller was Senior Vice President of Commercial and Industrial Development for Castle and Cooke, Inc. where for 17 years he was responsible for commercial, industrial and retail development for Hawaii's second largest private landowner.

Anthony M. Pilaro

Mr. Pilaro has been a director of the Company since August 1997. Presently, he serves as Chairman of CAP Advisers Limited, which maintains offices in Dublin, Ireland. He is also founder and Chairman of Excimer Vision Leasing L.P., a partnership engaged in the business of leasing Excimer laser systems. Mr. Pilaro has been involved in private international investment banking. He was a Founding Director and former Chief Executive Officer of DFS and a founder of the predecessor of VISX, Inc. A graduate of the University of Virginia `57, and the University of Virginia Law School `60, Mr. Pilaro practiced law in New York City through 1964.

R. Eric Montgomery

Mr. Montgomery has been a director of the Company since May 1998. He is an experienced consultant, researcher and entrepreneur in the oral care and cosmetic products industries, and has been granted over 65 US and foreign patents since 1981. Previously, from November 1997 until May 1998, he served as an independent consultant to the Company through Applied Dental Sciences, Inc. (Monterey, MA), the oral care products research and development firm of which he has been President since 1992. Mr. Montgomery is also the Founding Manager and President of OraCeutical LLC (Lee, MA), an organization dedicated to the development of innovative products and technologies for dentistry and consumer oral care. Oraceutical is currently engaged by the Company to provide technology development services. Mr. Montgomery's organizations have provided consulting services to and developed products for companies including The Dial Corporation, Natural White, Virbac SA, Zila Pharmaceuticals, ProHealth Laboratories, OPI Products, American Dental Hygienics, Premiere Dental, and Boots PLC. Mr. Montgomery is also President of IDEX Dental Sciences, Inc. (Lee, MA), an intellectual property holding firm established by Mr. Montgomery in March 1996.

Peter Schechter

32

Mr. Schechter was appointed a director of the Company in July 1999. Mr. Schechter is a founder of Chlopak, Leonard, Schechter and Associates, an international communications consulting firm. Previously, Mr. Schechter was Managing Director in charge of international business at the Sawyer/Miller Group, specializing in the management of international financial issues, political campaigns and country image programs. A graduate of the School of Advanced International Studies at Johns Hopkins University, Mr. Schechter has lived in Europe and Latin America and has extensive experience in the area of governmental relations. He is fluent in six languages.

Bradford Peters

Mr. Peters has been a director of the Company since December 1999. He is the President of Blackfin Capital, a privately held investment company based in New York. Prior to founding Blackfin Capital, from July 1993 to June 1998, Mr. Peters was with Morgan Stanley Private Wealth Management Group. Mr. Peters holds an MBA degree from Duke University.

L. Tim Pierce

Mr. Pierce was appointed a director in February 2003. Mr. Pierce is currently serving as an Executive Vice President and the Chief Financial Officer and Corporate Secretary of SBI and Company in Salt Lake City, Utah. He joined SBI and Company in April 1998. Mr. Pierce worked for Mrs. Fields' Original Cookies, Inc., Salt Lake City, Utah, from 1988 through 1998, where he served most

recently as Mrs. Fields' Senior Vice President, Chief Financial Officer, and Corporate Secretary. For twelve years from 1976 to 1988, Mr. Pierce served as an auditor with Price Waterhouse in New York City, Salt Lake City and Newport Beach, California, and with Deloitte & Touche in Salt Lake City. Mr. Pierce is a CPA. He received his Bachelor of Science in Accounting from Brigham Young University, Provo, Utah. Mr. Pierce is a former director of Mountain America Credit Union, a former director of various Mrs. Fields' entities, and is currently a director of Lante Corporation and Scient Japan. Mr. Pierce is a member of the American Institute of Certified Public Accountants, and the Utah Association of Certified Public Accountants. Mr. Pierce is considered by the Company to be an audit committee financial expert.

Harry Thompson

Mr. Thompson has served as a director of the Company since December 1999. He is currently the President of The Strategy Group and Managing Director of Swiss Army Brands, Inc. Prior to founding The Strategy Group, Mr. Thompson served in senior management of several core units of the Interpublic Group of Companies, one of the world's leading advertising groups. Mr. Thompson also has served as either manager or chairman of several telecommunication companies of The Galesi Group. Mr. Thompson holds an MBA degree from Harvard Business School.

Gerald Poch

Mr. Poch has served as a director of the Company since May 2000. He has served as Managing Director of Pequot Capital Management, Inc., a venture capital fund management company, since January 2000. From August 1998 through January 2000, he was a principal of Pequot Capital Management. From August 1996 to June 1998 he was the Chairman, President and Chief Executive Officer of GE Capital Information Technology Solutions, Inc., a technology solutions provider. Prior to that, he was a founder, and served as Co-Chairman and Co-President, of AmeriData Technologies, Inc., a value-added reseller and systems integrator of hardware and software systems. Mr. Poch is also a director of Andrew Corporation, a public company. In addition, Mr. Poch is a director of a number of private companies.

Dr. Gasper Lazzara, Jr.

Dr. Gasper Lazzara, Jr. has served as a director of the Company since 2000. He served as Chairman of the Board and a director of the Orthodontic Centers of America, Inc. ("OCA") since its inception in July 1994 through September 1998. He has served as Co-Chief Executive Officer of Orthodontic Centers since September 1998, and he served as Chief Executive Officer of OCA from July 1994 to September 1998. Dr. Lazzara also served as President of OCA from July 1994

33

to June 1997. From 1989 to 1994, Dr. Lazzara served as President or Managing Partner of certain predecessor entities of OCA. He is a licensed orthodontist and, prior to founding OCA, maintained a private orthodontic practice for over 25 years. He is a member of the American Association of Orthodontists and is a Diplomat of the American Board of Orthodontists.

Significant Employees or Consultants

Dr. John W. Warner

Dr. Warner accepted the position of Research and Development Director for the

Company in May 1998. Mr. Warner is an experienced research and technology consultant and entrepreneur who was one of the leading contributors to the development of ophthalmic applications of laser technology. Dr. Warner leads the Company's assessment of existing products and LATW development efforts. Dr. Warner has served as a consultant to Northwestern University in the areas of technology development and commercialization. From March 1986 to December 1990 he was the founder and CEO of Taunton Technologies, Inc., a predecessor of VISX, Inc., engaged in the business of developing and manufacturing Excimer laser systems to perform ophthalmic surgery.

COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

Section 16(a) of the Securities Exchange Act of 1934 requires the Company's officers, directors and persons who beneficially own more than 10 percent of a registered class of the Company's equity securities to file reports of ownership and changes in ownership with the Securities and Exchange Commission. Officers, directors and greater than 10 percent shareholders are required by regulation of the Securities and Exchange Commission to furnish the Company with copies of all Section 16(a) forms they file.

Based solely upon its review of the copies of such forms furnished to it during the fiscal year ended December 28, 2002, and representations made by certain persons subject to this obligation that such filings were not required to be made, the Company believes that all reports required to be filed by these individuals and persons under Section 16(a) were filed in a timely manner, except as follows:

Form 3 report of CAP Charitable Foundation filed December 20, 2002 to report a transaction dated April 16, 2002.

Form 3 report of CAP Charitable Foundation filed December 20, 2002, to report a transaction dated October 9, 2002.

Form 4 report of LCO Investments Limited filed December 23, 2002, to report a transaction dated October 9, 2002.

Form 4 report of Paul Dawson filed September 25, 2002, to report a transaction dated September 20, 2002.

Except as disclosed, the Company is not aware of any transactions in its outstanding securities by or on behalf of any director, executive officer or 10 percent holder, which would require the filing of any report pursuant to Section 16(a) during the fiscal year ended December 28, 2002, that has not been filed with the Securities and Exchange Commission.

ITEM 11. EXECUTIVE COMPENSATION

The following Summary Compensation Table shows compensation paid by the Company for services rendered during the nine-month transition period ended December 30, 2000 (the "Transition Period"), the fiscal year ended December 29, 2001 ("Fiscal 2001"), and the fiscal year ended December 28, 2002 ("Fiscal 2002") to John Reed, the Company's Chief Executive Officer, and to the Company's four most highly compensated executive officers during Fiscal 2002.

Summary Compensation Table

			Long T Compens
		Annual Compensation	Awar
Name and Principal Position	Period	Salary (\$)	Secur Under Opti SAR
John Reed, CEO	Fiscal 2002	\$ 225,000	0
	Fiscal 2001	252,600	0
	Transition Period	125,000	0
Paul Dawson CEO, BriteSmile International, Ltd.	Fiscal 2002	\$ 191,667	0
	Fiscal 2001	\$ 210,000	0
	Transition Period	133,333	0
Bruce Fleming President Officer	Fiscal 2002	\$ 175,000	0
Derek Correia	Fiscal 2002	\$ 400,079	0
ExecutiveVP, Marketing	Fiscal 2001	96,726	
Stephen Miller Executive VP, Manufacturing and Distribution	Fiscal 2002	\$ 150,000	0
	Fiscal 2001	231,789	0
	Transition Period	143,750	0

35

The following table lists individual grants of stock options made during the Company's last completed fiscal year as compensation for services rendered as an officer of the Company:

OPTION/SAR GRANTS IN FISCAL YEAR 2002

					Potential Annu
		Indivi	dual Grants		Appre
	Number of Securities Underlying	% of Total Options/SARs Granted to	Exercise or		
Name	Options/SARs Granted (#)	Employees in FY 2002	Base Price (\$/Share)	Expiration Date	5%

John L. Reed	0	0	N/A	N/A	N/A
Paul Dawson	0	0	N/A	N/A	N/A
Bruce Fleming	66 , 667	53	58.50	05/31/12	0
Steve Miller	0	0	N/A	N/A	N/A
Derek Correria	3,333	3	70.50	03/01/12	0

AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND DECEMBER 28, 2002 OPTION VALUES

Name	Shares Acquired on Exercise (#)	Value Realized (\$)	Number of Securities Underlying Unexercised Options at December 28, 2002 (1) Exercisable/Unexercisabl
John L. Reed (2)	0	0	36,667 /13,333
Paul Dawson (2)	0	0	0/0
Bruce Fleming	0	0	13,333/53,334
Steve Miller (2)	0	0	8,667/4,666
Derek Correria (2)	0	0	0/0

- (1) Potential unrealized value is calculated as the fair market value at December 28, 2002 (\$5.40 per share), less the option exercise \price, times the number of shares.
- (2) With respect to Messrs. Reed, Dawson, Miller and Correria, does not include an aggregate of 52,333 options voluntarily cancelled in September 2002, which have been regranted in March 2003 (\$10.77 per share) in connection with the Company's re-pricing program.

Compensation of Directors

36

Outside directors of the Company (non-employees) receive options to purchase 1,333 shares of common stock per year for each year during which they serve as a director. The exercise price of such options is 100% of the fair market price on the date of grant. Actual expenses incurred by outside directors are reimbursed.

Employment Contracts and Termination of Employment Arrangements

Certain of the Company's executive officers whose compensation is required to be reported in the Summary Compensation Table are parties to written employment agreements with the Company as follows:

John Reed

Pursuant to a letter agreement between the Company and John Reed dated January 20, 1999, Mr. Reed agreed to serve as Chief Executive Officer of the Company. The agreement provides that the Company will pay Mr. Reed \$250,000 a year for his services. Mr. Reed also received options to purchase 50,000 shares of the Company's common stock at the closing price on the date of the agreement, of which 43,333 have vested as of March 24, 2003. Mr. Reed's employment began in June 1999. On March 24, 2000, Mr. Reed was granted options to purchase 16,667 shares of the Company's common stock at the closing price on that date, of which 10,000 vested as of March 24, 2003.

Bruce Fleming

The Company entered into an employment agreement with Bruce Fleming on May 31, 2002. Under the terms of the agreement, Mr. Fleming has served as President of the Company. The Company pays Mr. Fleming an annual base salary of \$350,000. In addition, Mr. Fleming is eligible for incentive bonuses if certain targets are met. In addition, Mr. Fleming received options to purchase 66,667 shares of the Company's common stock. Options to purchase 13,333 shares vested on the date of the agreement; the remaining 53,334 options vest in equal installments over five years.

Paul Dawson

BriteSmile International, Ltd. entered into an employment agreement with Paul Dawson on April 19, 1999. Under the terms of the agreement, Mr. Dawson has served as Chief Executive Officer of BriteSmile International, a wholly-owned subsidiary of the Company. The Company pays Mr. Dawson \$16,666 per month for his services. Mr. Dawson is eligible for a bonus based on the number of paid teeth whitening procedures performed in a designated international area. The bonus will be paid in cash and Common Stock of the Company. In addition, Mr. Dawson received options to purchase 20,000 shares of the Company's common stock at the closing price on the date of the agreement. Options to purchase 6,667 shares vested on the date of the agreement. The remaining 13,333 options vest in equal installments over five years.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information as of March 12, 2003 regarding beneficial stock ownership of (i) all persons known to the Company to be beneficial owners of more than 5% of the outstanding common stock (the only class of stock of the Company); (ii) each director, the Chief Executive Officer, and the four highest paid executives of the Company other than the CEO, and (iii) all officers and directors of the Company as a group. Each of the persons in the table below has sole voting power and sole dispositive power as to all of the shares shown as beneficially owned by them, except as otherwise indicated.

Name and Address	Owned (1)		Shares(2)
Executive Officers	and Direct	ors	
Paul Dawson 36 Fitzwilliam Place Dublin 2, Ireland	15,160		*
John Dong 490 North Wiget Lane Walnut Creek, California 94598	2 , 667	(3)	*
Dr. Gasper Lazzara, Jr. 5000 Sawgrass Village Circle, Suite 28 Ponte Verda Beach, Florida 32082	38,609	(4)	1.6%
R. Eric Montgomery 29 Fairview Road P. O. Box 487 Monterey, Massachusetts 01245	33,279	(5)	1.4%
Bradford Peters Blackfin Capital, LLC 622 Third Avenue, 38th Floor New York, New York 10017	333,376	(6)	12.6%
Anthony M. Pilaro 36 Fitzwilliam Place Dublin 2, Ireland	1,506,696	(7)	52.1%
Gerald A. Poch Pequot Capital Management, Inc. 500 Nyala Farm Road Westport, Connecticut 06880	324,382	(8)	13.2%
John L. Reed 490 North Wiget Lane Walnut Creek, California 94598	180,427	(9)	7.1%
Peter Schechter Chlopak, Leonard, Schechter & Assoc. 3021 O Street, N.W. Washington, D.C. 20007	5,383	(10)	*
Harry Thompson 169 E. 78th Street New York, New York 10021	11,464	(11)	*
38			
Derek Correia 490 North Wiget Lane Walnut Creek, California 94598	160		*
Stephen Miller 490 North Wiget Lane	9,247	(12)	*

Walnut Creek, California 94598

Bruce Fleming 490 North Wiget Lane Walnut Creek, California 94598	13,334	(13)	*
All Officers and Directors as a Group (13 persons)	2,474,184	(14)	74.2%
5% Beneficial	Owners		
LCO Investments Limited 7 New Street St. Peter Port Guernsey, Channel Islands	1,506,696	(7)	52.1%
Pequot Capital Management, Inc. 500 Nyala Farm Road Westport, CT 06880	320,026	(15)	13.0%
Brad Peters c/o Blackfin Capital, LLC 622 Third Avenue, 38th Floor New York, New York 10017	333,376	(6)	12.6%

- * Constitutes less than 1%.
- (1) Include any options or warrants to purchase shares which are presently exercisable or exercisable within 60 days.
- (2) All percentages are calculated based upon a total number of shares outstanding which includes 2,428,539 shares of the Company issued and outstanding as of March 12, 2003, plus that number of options or warrants presently exercisable or exercisable within 60 days by the named security holder.
- (3) Includes options to purchase 2,667 shares at \$6.60 per share.
- (4) Includes 26,160 shares held indirectly through OCAI Two Limited Partnership, warrants to purchase 8,091 shares at \$75.00 per share, options to purchase 1,334 shares at \$138.75 per share, options to purchase 2,357 shares at \$75.00 per share, and options to purchase 667 shares at \$4.95 per share.
- (5) Includes 15,731 shares owned beneficially, options to purchase 2,213 shares at \$66.60 per share, options to purchase 13,334 shares at \$56.25 per share, options to purchase 1,334 shares at \$75.00 per share, and options to purchase 667 shares at \$4.95 per share.
- (6) Includes 113,639 shares owned of record and beneficially, warrants to purchase 49,608 shares at \$75.00 per share, the right to convert a note payable by the Company into 166,667 shares, options to purchase 1,462 shares at \$37.50 per share, options to purchase 1,333 shares at \$75.00 per share, and options to purchase 667 shares at \$4.95 per share.

- (7) Includes 567,593 shares owned of record and beneficially by LCO Investments Limited ("LCO"), the right to convert a note payable by the Company into 416,667 shares, 99,927 shares held indirectly through Pde P Tech Limited, a subsidiary of LCO, 1,800 shares held by AMP Trust, of which Mr. Pilaro is a beneficiary, 213,334 shares held by LCP II Trust, of which Mr. Pilaro's wife is a beneficiary, 66,667 shares held by ACP II Trust, of which one of Mr. Pilaro's adult sons not living in Mr. Pilaro's household is a beneficiary, 66,667 shares held by CAP II Trust, of which one of Mr. Pilaro's adult sons not living in Mr. Pilaro's household is a beneficiary, 19,520 shares held by various trusts of which CAP is a co-trustee, 45,920 warrants to purchase shares at \$75.00 per share held by LCO, 1,334 warrants to purchase shares held by PdeP, also exercisable at \$75.00 per share, 3,000 shares owned of record by the CAP Charitable Foundation and 4,267 shares owned of record by CAP Advisers Limited. LCO is a wholly owned subsidiary of the ERSE Trust. CAP is a co-trustee of the ERSE Trust. Mr. Pilaro, a director of the Company, is Chairman of CAP. Mr. Pilaro disclaims beneficial ownership of the shares held by LCO, PdeP Tech Limited, AMP Trust, LCP II Trust, ACP II Trust, CAP II Trust, the CAP Charitable Foundation, and CAP Advisers Limited and the trusts indicated above of which CAP is co-trustee.
- (8) Includes 147,444 shares held of record by Pequot Private Equity Fund II, L.P., 73,723 shares held of record by Pequot Partners Fund, L.P., 73,722 shares held of record by Pequot International Fund, Inc., 1,333 shares held of record by Pequot Scout Fund, L.P., warrants held of record by Pequot Private Equity Fund II, L.P. to purchase 11,902 shares at \$75.00 per share, warrants held of record by Pequot Partners Fund, L.P. to purchase 5,951 shares at \$75.00 per share, warrants held of record by Pequot International Fund, Inc. to purchase 5,951 shares at \$75.00 per share, (Pequot Private Equity Fund II, L.P., Pequot Partners Fund, L.P., and Pequot International Fund, Inc. are referred to collectively as, the "Pequot Funds") options held by Mr. Poch to purchase 1,333 shares at \$138.75 per share, options to purchase 2,356 shares at \$75.00 per share, and options to purchase 667 shares at \$4.95 per share. Mr. Poch is a Managing Director of Pequot Capital Management, Inc., which holds voting and dispositive power for all shares held of record by the Pequot Funds and may be deemed to beneficially own the shares held by the Pequot Funds. Mr. Poch disclaims beneficial ownership of the shares held of record by the Pequot Funds, except to the extent of his pecuniary interest therein.
- (9) Includes 53,698 shares owned beneficially, the right to convert a note payable by the Company into 83,334 shares, warrants to purchase 6,728 shares at \$75.00 per share, and options to purchase 36,667 shares at \$37.50 per share.
- (10) Includes 2,048 shares owned beneficially in a Revocable Living Trust, options to purchase 1,334 shares at \$168.75 per share, options to purchase 1,334 shares at \$75.00 per share, and options to purchase 667 shares at \$4.95 per share.
- (11) Includes options to purchase from LCO 6,667 shares at \$22.50 per share, options to purchase 1,334 shares at \$140.63 per share, options to purchase 1,462 shares at \$37.50 per share, options to purchase 1,334 shares at \$75.00 per share, and options to purchase 667 shares at \$4.95 per share.
- (12) Includes 580 shares owned beneficially and options to purchase 8,667 shares at \$41.25 per share.

- (13) Includes options to purchase 13,334 shares at \$58.50 per share.
- (14) Includes exercisable options and warrants to purchase 904,343 shares.
- (15) Includes 147,444 shares held of record by Pequot Private Equity Fund II, L.P., 73,723 shares held of record by Pequot Partners Fund, L.P., 73,722 shares held of record by Pequot International Fund, Inc., 1,333 shares held of record by Pequot Scout Fund, L.P., warrants held of record by Pequot Private Equity Fund II, L.P. to purchase 11,902 shares at \$75.00 per share, warrants held of record by Pequot Partners Fund, L.P. to purchase 5,951 shares at \$75.00 per share, warrants held of record by Pequot International Fund, Inc. to purchase 5,951 shares at \$75.00 per share.

40

Equity Compensation Plan Information

See footnote 10, "Shareholder's Equity," to the Financial Statements included with this Report for a description of securities authorized for issuance under equity compensation plans of the Company.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

November 2002 Sale of Convertible Notes

On November 20, 2002, the Company sold to two investors in a private placement 2% convertible notes that are due and payable on November 20, 2005 (the "November 2002 Notes") in a private placement. The November 2002 Notes are convertible into shares of common stock of the Company at a conversion rate of \$6.00 per share. The two investors who purchased the November 2002 Notes, both affiliates of the Company, are: LCO Investments Limited (\$2,500,000) and Bradford G. Peters (\$1,000,000). The CEO of the Company has agreed to fund an additional \$500,000 in 2003 under the same terms. LCO Investments Limited is the Company's major shareholder. LCO is a wholly owned subsidiary of the ERSE Trust. CAP Advisers Limited is a co-trustee of the ERSE Trust. Mr. Pilaro, a director of the Company, is Chairman of CAP. John L. Reed is a shareholder, the Chief Executive Officer, and a director of the Company. Brad Peters is a shareholder and a director of the Company.

LCO Properties Sublease

On December 1, 1999 the Company, as lessee, entered into an Agreement of Sublease with LCO Properties, Inc., a Delaware corporation, as lessor. LCO Properties, Inc. is affiliated with the Company's principal shareholder, LCO Investments Limited ("LCO"). The Sublease covers approximately 4,821 square feet of space located in the building known as 16-18 West 57th Street in the Borough of Manhattan, New York City. The sublease term is for ten years and calls for initial lease payments of \$402,000 per year, subject to increase in the event of increases in the rent payable under the parent lease for the property between LCO Properties, Inc., and its lessor.

Harry Thompson Consulting Agreement

In August 1999, Harry Thompson, a director of the Company, agreed to provide marketing consulting services to the Company. In consideration for Mr.

Thompson's services to the Company, and pursuant to a letter agreement dated August 17, 1999, the Company's principal shareholder, LCO, granted Mr. Thompson the right to purchase from LCO up to 6,667 shares of common stock of the Company at a price of \$33.75 per share. The option to purchase from LCO expires on August 31, 2004.

Public Relations Services Agreement

On April 7, 1999, the Company entered into a Letter Agreement with Chlopak, Leonard, Schechter and Associates ("CLS"), a public relations firm in Washington, D.C. Pursuant to the agreement, CLS provides public relations advice and serves as communications counselors to the Company for consideration of \$18,000 per month, plus expenses. The agreement was entered into for a minimum of six months, and remains in force. Peter Schechter, a director of the Company, is one of three managing partners of CLS.

Oral Health Clinical Services Agreement

On March 24, 1999, the Company entered into a Consulting Agreement with Oral Health Clinical Services, LLC, ("Oral Health") Salim A. Nathoo, and R. Eric Montgomery. Mr. Montgomery is a director of the Company. Pursuant to the agreement, Oral Health and Nathoo will devote their services to obtaining American Dental Association (ADA) Certification for the BriteSmile 2000 Tooth Whitening Procedure. The term of the contract is for two years or until ADA Certification, whichever is earlier. In consideration for the services, the Company granted 5,000 stock options to Dr. Nathoo, which have vested. The Company will grant up to 15,000 additional stock options, of which the number and exercise price is dependent upon obtaining ADA Certification, at the date the Certification is obtained. Certification has not been obtained and no payments were made by the Company under the contract during Fiscal 2002.

41

Oraceutical Agreement

On November 27, 2000, the Company entered into a Consulting Agreement with Oraceutical, LLC. R. Eric Montgomery, a director of the Company, is the founding Manager and President of Oraceutical. Pursuant to the agreement, Oraceutical provides technology development services to the Company for various light-activated teeth whitening products and procedures. In consideration for its services, Oraceutical has been paid \$25,000 a month, plus options to purchase 13,333 shares of common stock, subject to vesting provisions, exercisable at \$56.25 per share.

EVL Lease Agreement

On December 29, 2000, as amended in February 2001, March 2002, September 2002, and January 2003, the Company secured a lease line of credit of up to \$15 million from Excimer Vision Leasing L.P. ("EVL"). Anthony Pilaro, the Company's Chairman, serves as Chairman of EVL. An affiliate of LCO Investments Inc., the Company's largest shareholder, owns 70% of EVL. EVL Loan Agreement

On March 1, 2001, the Company borrowed \$2.5 million from EVL for general working capital. The loan matures on May 10, 2006 and may be prepaid at any time without penalty. Payments under the loan consist of "fixed payments" of interest, "variable payments" of principal and interest and a "final payment" of principal. An initial fixed payment of \$10,417 was paid on April 1, 2001.

Additional fixed monthly payments of \$12,500 are due during the loan period. Variable payments are \$25 for each LATW procedure performed at the Company's 14 Centers. For Fiscal 2002, Fiscal 2001 and the Transition Period variable payments totaled \$717,000, \$664,000 and \$0, respectively, and the unpaid balance of the loan was \$1,583,000 at December 28, 2002. The final payment, due at maturity will be the amount by which the aggregate of variable payments paid during the term of the loan is less than the original \$2.5 million principal amount of the loan.

CAP Advisers Line of Credit

In December 2001, as amended in March, July 2002 and January 2003, BriteSmile International, a wholly-owned subsidiary of the Company, entered into Credit and Security Agreements with CAP Advisers which provide for a \$6.5 million line of credit facility of which, \$1.5 million is for the purchase of capital equipment. As of December 28, 2002, \$4.7 million has been drawn on the line. Mr. Pilaro, the Company's Chairman, is also Chairman of CAP Advisers. Cap Advisers is the sole trustee of the ERSE Trust. The ERSE Trust owns 100% of LCO, the Company's major shareholder.

CAP Advisers Center Loan

In April 2003, the Company's Audit Committee and it's Board of Directors approved a term sheet from CAP Advisers for a \$2.5 million Center Loan (the "2003 Center Loan") to be used for capital expenditures and other specific revenue generating initiatives to be agreed and defined by BriteSmile and Cap Advisers and up to \$800,000 for general working capital. Interest is fixed at 6%, payable monthly, with Cap Advisers having the right to reset the interest rate to 200bps over 1 year LIBOR after giving BriteSmile 30 days notice. A variable fee payment of \$25 per procedure performed on the existing 127 Center chairs will commence on May 11, 2006, and continue until May 10, 2011. Variable fees will be payable 40 days after the end of the month in which the procedures are performed, except for fees due for April/May 2011 which will become payable on the maturity date. On an annualized basis the first \$500,000 of variable fees will be applied to the principal such that the \$2.5M will be fully repaid over 5 years commencing May 11, 2006. Variable payments in excess of the annual amortization of \$500,000 are deemed additional interest to Cap Advisers.

ITEM 14. CONTROLS AND PROCEDURES

Explanation of Disclosure Controls and Procedures
Our chief executive officer and our chief financial officer, after evaluating
the effectiveness of the Company's "disclosure controls and procedures" (as
defined in Exchange Act Rules 13a-14(c) and 15d-14(c)) as of a date (the
"Evaluation Date") within 90 days of the filing date of this annual report, have
concluded that as of the Evaluation Date, our disclosure controls and procedures
were adequate and effective and designed to ensure that material information
relating to us and our consolidated subsidiaries would be made known to them by
others within those entities.

Changes in Internal Controls

There were no significant changes in our internal controls or in other factors that could significantly affect our internal controls subsequent to the Evaluation Date, including any corrective actions with regard to significant deficiencies and material weaknesses.

PART IV.

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K

42

(a)	The following documents are filed as a part of this Report: 1. Financial Statements	
	Report of Independent Auditors	F-2
	Report of Independent Auditors	F-3
	Consolidated Balance Sheets for the 52-week periods ended December 28, 2002 and December 29, 2001.	F-4
	Consolidated Statements of Operations for the 52-week periods ended December 28, 2002 and December 29, 2001 and the 39-week period ended December 30, 2000.	F-6
	Consolidated Statements of Cashflows for the 52-week periods ended December 28, 2002 and December 29, 2001 and the 39-week period ended December 30, 2000.	F-8
	Consolidated Statements of Shareholders' Equity for the 52-week periods ended December 28, 2002 and December 29, 2001 and the 39-week period	
	ended December 30, 2000.	F-9
	Notes to Consolidated Financial Statements.	F-10
	2. Financial Statement Schedules Schedule of Valuation and Qualifying Accounts for the 52-week periods ended December 28, 2002 and December 29, 2001 and the 39-week period ended December 30, 2000.	F-33
	3. Exhibits	
Exhibit Num Per Item 60 Regulation	1 of	
2	Asset Purchase Agreement and Plan of Reorganization by and among BriteSmile, Inc., an Alabama corporation, BriteSmile, Inc., a Utah corporation, and David K. Yarborough, together with the exhibits and schedules forming part of the Asset Purchase Agreement (incorporated by reference to the Company's Current Report on Form 8-K dated March 7, 1996).	
3.0	Articles of Restatement of the Articles of Incorporation of the Company as filed with the Utah Division of Corporations and Commercial Code on January 17, 2003 (filed herewith).	
3.0	2 Bylaws adopted May 2, 1996, (incorporated by reference to	

the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1996).

- 3.03 Amendment to Bylaws adopted July 23, 1999 (incorporated by reference to the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 1999).
- 10.01 1990 Stock Option Plan for Employees of the Company (incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1996).
- 10.02 Securities Purchase Agreement dated April 1, 1996 for 300,000 shares of common stock and

43

Options to Purchase 1,000,000 shares of common stock at \$20 per share, between the Company, LCO Investments Limited, Pinnacle Fund L.P., and Richard S. Braddock (incorporated by reference to the Current Report on Form 8-K of the Company dated April 1, 1996).

- 10.03 Registration Rights Agreement dated April 1, 1996 between the Company, LCO Investments Limited, Richard S. Braddock, and Pinnacle Fund, L.P. (incorporated by reference to the Current Report on Form 8-K of the Company dated April 1, 1996).
- Securities Purchase Agreement dated May 8, 1997 for 428,572 shares of common stock and Options to Purchase 500,000 shares of common stock at \$9.00 per share, among the Company, LCO Investments Limited, and Richard S. Braddock (incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1997).
- 10.05 Registration Rights Agreement dated May 8, 1997 among the Company, LCO Investments Limited, and Richard S. Braddock (incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1997).
- 10.06 Stock Purchase Agreement dated as of May 4, 1998 for 1,860,465 shares of common stock, between the Company and LCO Investments Limited (incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1998).
- 10.07 Registration Rights Agreement dated as of May 4, 1998

between the Company and LCO Investments Limited (incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended March 31, 1998).

- 10.08 Employment Letter dated January 20, 1999 (effective June 2, 1999) between the Company and John L. Reed (incorporated by reference to the Company's Annual Report on Form 10-KSB for the year ended March 31, 1999).
- 10.09 Employment Letter dated April 19, 1999 between the Company's subsidiary, BriteSmile International, Limited, and

Paul Dawson (incorporated by reference to the Company's Annual Report on Form 10-KSB for the year ended March 31, 1999).

- 10.10 Revised 1997 Stock Option and Incentive Plan of the Company, as amended through June 20, 2001 (incorporated by reference to the Company's Annual Report on Form 10-K for the 52 weeks ended December 29, 2001).
- 10.11 Form of Option Agreement between the Company and certain directors of the Company (incorporated by reference to the Company's Annual Report on Form 10-K for the 52 weeks ended December 29, 2001).
- 10.12 Form of Option Agreement between the Company and certain employees of the Company (incorporated by reference to the Company's Annual Report on Form 10-K for the 52 weeks ended December 29, 2001).
- 10.13 Form of Stock Purchase Agreement dated as of June 3, 1999, between the Company and purchasers who acquired shares at a 5% discount to the 10-day average market price preceding closing (incorporated by reference to the Company's Current Report on Form 8-K as filed June 21, 1999).
- 10.14 Registration Rights Agreement dated as of June 3, 1999 between the Company and the non-management purchasers (incorporated by reference to the Company's Current Report on Form 8-K as filed June 21, 1999).
- 10.15 Amended and Restated Registration Rights Agreement dated as of June 3, 1999 between the

44

Company and the management purchasers (incorporated by reference to the Company's Current Report on Form 8-K as filed June 21, 1999).

- 10.16 Form of Stock Purchase Agreement dated as of June 3, 1999 between the Company and purchasers who acquired shares of common stock of the Company at a 5% discount to the 10-day average market price preceding closing (incorporated by reference to the Company's Current Report on Form 8-K dated June 4, 1999).
- 10.17 Registration Rights Agreement dated as of June 3, 1999 between the Company and certain non-management purchasers in the June 1999 Private Placement (incorporated by reference to the Company's Current Report on Form 8-K dated June 4, 1999).
- 10.18 Amended and Restated Registration Rights Agreement dated as of June 3, 1999 between the Company and certain management purchasers (incorporated by reference to the Company's Current Report on Form 8-K as filed June 4, 1999).
- 10.19 Stock Purchase Agreement dated as of January 12, 1999 between the Company and the Pequot investment funds ("Pequot

Funds") (incorporated by reference to the Company's Current Report on Form 8-K dated January 18, 2000).

- 10.20 Registration Rights Agreement dated as of January 18, 2000 between the Company and the Pequot Funds (incorporated by reference to the Company's Current Report on Form 8-K dated January 18, 2000).
- Voting and Co-sale Agreement dated as of January 18, 2000 between the Company, the Pequot Funds and LCO Investments Ltd. (incorporated by reference to the Company's Current Report on Form 8-K dated January 18, 2000).
- 10.22 Agreement of Sublease dated December 1999 between the Company and LCO Properties, Inc. (incorporated by reference to the Company's Annual Report on Form 10-KSB for the fiscal year ended April 1, 2000).
- Securities Purchase Agreement dated as of June 27, 2000 between the Company and certain purchasers of 5% Convertible Subordinated Notes (incorporated by reference to the Company's Transition Report on Form 10-K for the Nine-month Transition Period ended December 30, 2000).
- Form of Convertible Notes issued pursuant to the Securities Purchase Agreement dated as of June 27, 2000 (incorporated by reference to the Company's Transition Report on Form 10-K for the Nine-month Transition Period ended December 30, 2000).
- Form of Warrants granted to note purchasers pursuant to the Securities Purchase Agreement dated as of June 27, 2000 (incorporated by reference to the Company's Transition Report on Form 10-K for the Nine-month Transition Period ended December 30. 2000).
- Form of Registration Rights Agreement between the Company of the purchasers of Notes pursuant to the Securities Purchase Agreement dated as of June 27, 2000 (incorporated by reference to the Company's Transition Report on Form 10-K for the Nine-month Transition Period ended December 30, 2000).
- Amendment Agreement dated as of August 3, 2000 between the Company and the purchasers of notes identified therein (incorporated by reference to the Company's Transition Report on Form 10-K for the Nine-month Transition Period ended December 30, 2000).
- 10.28 Note Purchase Agreement dated December 5, 2000 between the Company and LCO Investments Limited (incorporated by reference to the Company's Current Report on Form 8-K

45

dated December 5, 2000).

10.29 Convertible Promissory Note dated December 5, 2000 in the principal amount of \$5,000,000 (incorporated by reference to

the Company's Current Report on Form 8-K dated December 5, 2000).

- 10.30 Warrant to Purchase 250,000 Shares of common stock of the Company dated December 5, 2000 (incorporated by reference to the Company's Current Report on Form 8-K dated December 5, 2000).
- Amended and Restated Agreement between Excimer Vision Leasing L.P. and the Company dated February 2001 (incorporated by reference to the Company's Transition Report on Form 10-K for the Nine-month Transition Period ended December 30, 2000).
- Amendment dated September 18, 2002 to Amended and Restated Agreement between Excimer Vision Leasing L.P. and the Company dated February 2001 (filed herewith).
- 10.33 Amendment dated January 1, 2003 to Amended and Restated Agreement between Excimer Vision Leasing L.P. and the Company dated February 2001 (filed herewith).
- 10.34 Loan Agreement between Excimer Vision Leasing L.P. and the Company dated as of March 1, 2001 (incorporated by reference to the Company's Transition Report on Form 10-K for the Nine-month Transition Period ended December 30, 2000).
- Unsecured Credit Agreement between BriteSmile International and CAP Advisers Limited dated March 2002 (incorporated by reference to the Company's Annual Report on Form 10-K for the 52 weeks ended December 29, 2001).
- 10.36 Credit and Security Agreement dated December 13, 2001 between BriteSmile International and CAP Advisers Limited (incorporated by reference to the Company's Annual Report on Form 10-K for the 52 weeks ended December 29, 2001).
- Supplemental Agreement dated March 2002 to Credit and Security Agreement dated December 13, 2001 between BriteSmile International and CAP Advisers Limited (incorporated by reference to the Company's Annual Report on Form 10-K for the 52 weeks ended December 29, 2001).
- Supplemental Agreement dated July 19, 2002 to Credit and Security Agreement dated December 13, 2001, as amended, and to Unsecured Credit Agreement dated March 8, 2002 (incorporated by reference to the Quarterly Report on Form 10-Q of the Company for the 13 weeks ended June 29, 2002).
- Supplemental Agreement dated January 9, 2003 to Credit and Security Agreement dated March 2002 (filed herewith).
- 10.40 Amendment to Lease Agreement between Excimer Vision
 Leasing L.P. and the Company dated March 8, 2002
 (incorporated by reference to the Company's Annual Report on
 Form 10-K for the 52 weeks ended December 29, 2001).
- 10.41 Form of Guaranty of Fiscal 2002 Shortfall Summary of Terms dated March 2002 in connection with commitments from certain shareholders and/or directors of the Company to secure up to \$4 million of additional working capital (incorporated by reference to the Company's Annual Report on Form 10-K for

the 52 weeks ended December 29, 2001).

10.42 Form of Convertible Note Purchase Agreement used in connection with November 20, 2002 convertible note offering (incorporated by reference to the Current Report on Form 8-K of the

46

Company filed on November 25, 2002).

- 10.43 Form of Convertible Promissory Note issued in connection with November 20, 2002 convertible note offering (incorporated by reference to the Current Report on Form 8-K of the Company filed on November 25, 2002).
- 10.44 Employment Agreement dated May 31, 2002 between the Company and Bruce Fleming (incorporated by reference to the Quarterly Report on Form 10-Q of the Company for the 13 weeks ended June 29, 2002).
- 21 Subsidiaries of the Company (filed herewith).
- 23.1 Consent of Independent Auditors (filed herewith).
- 23.2 Consent of Independent Auditors, Ernst & Young, LLP
 (filed herewith).
- 99.1 Certification of John L. Reed pursuant to Section 906 of the Sarbanes Oxley Act of 2002 (filed herewith).
- 99.2 Certification of John C. Dong pursuant to Section 906 of the Sarbanes Oxley Act of 2002 (filed herewith).

(b) Reports on Form 8-K

The Company filed a Current Report on Form 8-K on November 25, 2002 for the purpose of reporting the sale of the Company's 2% convertible notes that are due and payable on November 20, 2005.

47

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

BriteSmile, Inc.

By: /s/ John L. Reed

John L. Reed

Chief Executive Officer

By: /s/ John C. Dong

John C. Dong

EVP, Chief Financial Officer

Date: April 9, 2003

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ A.M. Pilaro	Chairman of the Board of Directors	April 9, 2003
Anthony M. Pilaro		
/s/ John L. Reed	Chief Executive Officer	April 9, 2003
John L. Reed	and Director (Principal Executive Officer)	
/s/Bruce Fleming	Director	April 9, 2003
Bruce Fleming		
/s/ R. Eric Montgomery	Director	April 9, 2003
R. Eric Montgomery		
/s/ Gerald Poch	Director	April 9, 2003
Gerald Poch		
/s/ Dr. Gasper Lazzara, Jr.	Director	April 10, 2003
Dr. Gasper Lazzara, Jr.		
/s/ Brad Peters	Director	April 10, 2003
Brad Peters		
/s/ Harry Thompson	Director	April 10, 2003
Harry Thompson		
/s/ Peter Schechter	Director	April 10, 2003
Peter Schechter		
/s/ Tim Pierce	Director	April 10, 2003
Tim Pierce		

CHIEF EXECUTIVE OFFICER CERTIFICATION

I, John L. Reed, Chief Executive Officer of BriteSmile, Inc., certify that:

- 1. I have reviewed this Annual Report on Form 10-K of BriteSmile, Inc.
 (the "Registrant");
- 2. Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report;
 - 3. Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Annual Report;
 - 4. The Registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and have:
 - a) designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared;
 - b) evaluated the effectiveness of the Registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this Annual Report (the "Evaluation Date"); and
 - c) presented in this Annual Report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
- 5. The Registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the Registrant's auditors and the audit committee of Registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the Registrant's ability to record, process, summarize and report financial data and have identified for the Registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal controls; and
- 6. The Registrant's other certifying officers and I have indicated in this Annual Report whether or not there were significant changes in

internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: April 9, 2003

/s/ John L. Reed

John L. Reed Chief Executive Officer (Principal Executive Officer)

49

CHIEF FINANCIAL OFFICER CERTIFICATION

- I, John C. Dong, Chief Financial Officer of BriteSmile, Inc., certify that:
- 1. I have reviewed this Annual Report on Form 10-K of BriteSmile, Inc.
 (the "Registrant");
- 2. Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report;
 - 3. Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Annual Report;
 - 4. The Registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and have:
 - a) designed such disclosure controls and procedures to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared;
 - b) evaluated the effectiveness of the Registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this Annual Report (the "Evaluation Date"); and
 - c) presented in this Annual Report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

- 5. The Registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the Registrant's auditors and the audit committee of Registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the Registrant's ability to record, process, summarize and report financial data and have identified for the Registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal controls; and
- 6. The Registrant's other certifying officers and I have indicated in this Annual Report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: April 9, 2003 /s/ John C. Dong

John C. Dong Chief Financial Officer (Principal Financial and Accounting Officer)

50

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BRITESMILE, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Auditors F-2
Report of Independent Auditors F-3
Consolidated Balance SheetsF-4
Consolidated Statements of OperationsF-6
Consolidated Statements of Cash FlowsF-8
Consolidated Statements of Shareholders' EquityF-9
Notes to Consolidated Financial StatementsF-10

F-1

Report of Independent Auditors

The Board of Directors and Shareholders, BriteSmile, Inc.

We have audited the accompanying consolidated balance sheet of BriteSmile, Inc. and subsidiaries as of December 28, 2002 and the related consolidated statements of operations, shareholders' equity, and cash flows for the 52 week period ended December 28, 2002. Our audit also included the financial statement schedule for such period listed in the Index at Item 15(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the 2002 financial statements referred to above present fairly, in all material respects, the consolidated financial position of BriteSmile, Inc. and subsidiaries at December 28, 2002 and the consolidated results of their operations and their cash flows for the 52 week period ended December 28, 2002, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule for such period, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

/s/ Deloitte & Touche, LLP

March 7, 2003 (April 7, 2003 as to paragraphs 7,8 and 9 of Note 1) Oakland, California

F-2

Report of Ernst & Young, LLP, Independent Auditors

The Board of Directors and Shareholders BriteSmile, Inc.

We have audited the accompanying consolidated balance sheet of BriteSmile, Inc. as of December 29, 2001 and the related consolidated statements of operations, shareholders' equity, and cash flows for the 52 weeks ended December 29, 2001 and the 39 weeks ended December 30, 2000. Our audits also included the financial statement schedule listed in the Index at Item 15(a). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audit.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of BriteSmile, Inc. at December 29, 2001 and the consolidated results of its operations and its cash flows for the 52 weeks ended December 29, 2001 and the 39 weeks ended December 30, 2000, in conformity with accounting principles generally accepted in the United States. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

/s/Ernst & Young LLP

March 8, 2002, except for Note 1 as to which the date is March 28, 2002 Walnut Creek, California

F-3

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BRITESMILE, INC.
CONSOLIDATED BALANCE SHEETS
ASSETS
(In Thousands, except share data)

December 28, 2002

CURRENT ASSETS:

Cash and cash equivalents

\$ 3,527

Trade accounts receivable, net of allowances of \$506 and \$615, respectively Inventories Prepaid expenses and other Notes receivable-current portion		2,364 2,502 189
Total current assets		8,582
PROPERTY, EQUIPMENT AND IMPROVEMENTS:		
Furniture, fixtures and equipment		7,600
Teeth whitening equipment		16,682
Leasehold improvements		10,171
		34,453
Less accumulated depreciation and amortization		(14,164)
Net property, equipment and improvements		20,289
INVESTMENTS, RESTRICTED AS TO USE		843
OTHER ASSETS		1,385
TOTAL ASSETS	\$	31,099
	=====	

See accompanying notes to consolidated financial statements.

F-4

BRITESMILE, INC. CONSOLIDATED BALANCE SHEETS (continued)

LIABILITIES AND SHAREHOLDERS' EQUITY (In Thousands, except share data)

December 28, 2002

CURRENT LIABILITIES:

Accounts payable Accrued liabilities	\$ 4,793 4,403
Deferred revenue	819
Accrual for store closures	201
Note payable to related party	500
Subordinated convertible debenture, net of discount	749
Capital lease obligation with related party- current portion	701
capital lease obligation with lefated party current polition	
Total current liabilities	 12 , 166
LONG TERM LIABILITIES	
Capital lease obligations with related party -	
less current portion	1 , 885
Accrual for store closure	1,035
Note payable to related party, less current portion	1,083
Line of credit borrowings	4,714
Accrued variable rent payable to EVL	2 , 150
Convertible debenture 2%	3 , 500
Other long term liabilities	 767
Total long term liabilities	 15 , 134
Total liabilities	 27,300
COMMITMENTS AND CONTINGENCIES	
SHAREHOLDERS' EQUITY:	
Common stock, \$.001 par value; 50,000,000 shares authorized; 2,428,464 and 2,415,131 shares issued and outstanding as of December 28,	
2002 and December 29, 2001, respectively	36
Additional paid-in capital	139,418
Accumulated deficit	 (135 , 655
Total shareholders' equity	 3 , 799
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 31 , 099

See accompanying notes to consolidated financial statements.

F-5

CONSOLIDATED STATEMENTS OF OPERATIONS (In Thousands, except share data)

	52 Weeks Ended December 28, 2002	December 2001
REVENUES:		
NEVENOES.		
Center whitening fees, net	\$ 12,738	\$ 1
Associated center whitening fees, net	22,460	2
Product sales	4 , 125	
Total revenues, net	39,323	4
OPERATING COSTS AND EXPENSES:		
Operating and occupancy costs	14,671	1
Selling, general and administrative expenses	34,480	4
Research and development expenses	923	
Depreciation and amortization	6,099 304	
Restructuring expense Impairment charges on leasehold improvements	504	
Loss on sale/leaseback transaction		
	-	
Total annuating south and assessed	F.C. 477	
Total operating costs and expenses	56,477 	
Loss from operations	(17,154)	(2
Interest expense	(1,603)	(
Interest income	66	
Loss before income tax provision and cumulative effect of change in accounting principle	(18,691)	(26
	. , ,	,
Income tax provision	80	
Net loss before cumulative effect of change in accounting principle	(18,771)	(2
Cumulative effect of change in accounting principle	(10, 771)	(2
(Note 3)		
Net loss	\$ (18,771)	\$ (2
	. (,)	, (3
DEEMED DIVIDEND RELATED TO WARRANTS	307	
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	\$ (19,078)	\$ (2
	========	====

Basic and diluted net loss per share before cumulative effect of change in accounting principle	\$ (7.86) 	\$ (====
Cumulative effect of change in accounting principle	-	====
Basic and diluted net loss per share	\$ (7.86) =====	\$ (=====
Weighted average shares - basic and diluted	2,427,412	2 , 23

See accompanying notes to consolidated financial statements.

F-6

BRITESMILE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands)

	E: Decei	Weeks nded mber 28, 2002	52 V End Decemb 20
CASH FLOWS USED IN OPERATING ACTIVITIES:			
Net loss	\$	(18,771)	\$
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization		6,099	
Write off of property and equipment		76	
Amortization of discount on debt		20	
Loss on sale/leaseback transaction		_	
Impairment charges on leasehold improvements		_	
Debt conversion expense, including accrued interest			
converted to equity		724	
Costs recognized for issuance of stock and stock options Changes in assets and liabilities:		1,013	
Trade accounts receivable		1,947	
Inventories		38	
Prepaid expenses and other		234	
Other assets		113	
Accounts payable		(719)	
Accrued liabilities		1,594	
Deferred revenue		56	
Other long-term liabilities		(64)	

Net cash used in operating activities	(7,640)	
CASH FLOWS USED IN INVESTING ACTIVITIES: Proceeds from sales of assets Repayment of notes receivable Purchase of property and equipment	- 391 (3,948)	
Net cash used in investing activities	(3,557)	
CASH FLOWS FROM FINANCING ACTIVITIES: Payments of capital lease obligation Principal payments on long-term debt Proceeds from issuance of debt Borrowings from line of credit Proceeds from common stock offerings Proceeds from exercise of stock options and warrants Net cash provided by financing activities	(592) (500) 3,500 4,714 - 440	
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD	(3,635) 7,162	
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	\$ 3,527	\$ ====

See accompanying notes to consolidated financial statements

F-7

BRITESMILE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (continued) (In Thousands)

> December 28, December 29, 2002 ____

52 Weeks 52 Weeks Ended Ended 2001

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Cash paid for interest	\$	617	\$	291
Cash paid for income taxes	\$	80	\$ =====	57
SUPPLEMENTAL DISCLOSURE OF NON CASH ITEMS: Conversion of debt, including accrued interest of \$132 equity	\$ =====	-	\$	5 , 132
Fair value of stock options and warrants issued to consultants	\$	_	\$	-
Fair value of warrants issued in debt financing arrangements	\$	158	\$	_
Equipment acquired under capital lease obligations	\$		\$ =====	2 , 373

See accompanying notes to consolidated financial statements

F-8

BRITESMILE, INC. AND SUBSIDIARIES
Consolidated Statements of Shareholders' Equity
(In Thousands)

	Common Shares	Additional Shares Paid-In Amount Capital		
Balance at April 1, 2000	1,591	\$ 24	\$ 73,389	\$ (4
Exercise of stock options	10	-	227	

Beneficial conversion related			0.070	
to debt financing	_	_	3 , 378	
Income tax benefit on exercise of stock options	_	_	3 , 253	
Valuation allowance for income	_	=	3,433	
tax benefit on exercise of				
	_	_	(3,253)	
stock options	-	_	(3 , 253) 479	
Stock option compensation cost Conversion of long-term debt to	_	=	412	
conversion of long-term debt to	21 6	5	10 200	
	316	5	19,390	
Issuance of warrants in connection			2 705	
with financing agreement	_	_	2,705	
Net loss and comprehensive loss	- 			(4
Balance at December 30, 2000	1,917	29	99 , 568	(9
Exercise of stock options	65	1	4,124	
Stock option compensation cost	_	_	1,097	
Conversion of long-term debt to			•	
common stock	68	1	5 , 131	
Exercise of warrants	7	_	559	
Private placement of common stock, net of				
placement fees of \$1,400 and fair				
value of warrants issued to placement				
agent	358	5	26,618	
Net loss and comprehensive loss			,	
100 100 100	-	-	-	(2
-				
Balance at December 29, 2001	2,415	36	137,097	(11
Deemed dividend related to warrants	_	_	307	
Exercise of stock options	13	_	440	
Stock option compensation and warrant cost	_	_	1,574	
Net loss and comprehensive loss	_	_	_	(1
Balance at December 28, 2002	2,428	\$ 36	\$139,418	\$(13
=		======	=======	====

See accompanying notes to consolidated financial statements

F-9

BriteSmile, Inc.
Notes to Consolidated Financial Statements

1. Description of Business and Liquidity

BriteSmile, Inc., a Utah corporation ("BriteSmile" or the "Company"), and its affiliates develop, and sell advanced teeth whitening products, services and technology. The Company's operations include the development of technologically advanced teeth whitening processes that are distributed in professional salon settings known as BriteSmile Professional Teeth Whitening Centers ("Centers"). The Company also offers its products and technologies through arrangements with existing independent dental offices known as BriteSmile Professional Teeth Whitening Associated Centers ("Associated Centers").

Centers are located in major metropolitan areas nationwide and offer clients a salon-like environment dedicated solely to the business of teeth whitening. Centers are staffed by licensed dentists and trained dental assistants. As of the date of this report, the Company has 14 Centers in operation. As an alternative to the Company-owned Centers, consumers can visit an Associated Center, where a local dentist administers the BriteSmile procedure in the dentist's established office. To date, the Company has entered into contracts with 4,636 Associated Centers, including 3,321 in the United States, and 1,315 in 67 countries outside the United States. The Company is not engaged in the practice of dentistry. Each licensed dentist who operates a Center or Associated Center maintains full control over dental matters, including the supervision of dental auxiliaries and the administration of the LATW procedure.

The Company developed its current teeth whitening technology (the "BriteSmile Light Activated Teeth Whitening System," "BS2000" or "LATW") and began distribution in 1999. In November 1999 the Company introduced its new BriteSmile 3000 LATW keycard system (the "BS3000") to Associated Centers. The BS3000, a mobile version of the BS2000, can be installed quickly and provides improved flexibility and mobility in dental offices. In May 2001, the Company introduced its more versatile mobile device, the BS3000PB, which is the device currently shipped to Associated Centers. The BS2000, BS3000, and BS3000PB teeth whitening devices utilize a light technology. The unique delivery arm of these devices permits blue green light to reach all 16 front teeth simultaneously, whitening the teeth by activating BriteSmile's wavelength-specific gel during three consecutive twenty-minute sessions.

Statement of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and related Information," ("SFAS No. 131") established standards for reporting information about operating segments in financial statements. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief decision maker, or chief decision-making group, in deciding how to allocate resources and in assessing performance. Our President and CEO is our chief decision maker. Our business is focused on one industry segment, products and procedures to whiten teeth. All of our revenues and profits are generated through the sale, licensing, and service of products for this one segment. Revenue from outside the United States of America in Fiscal 2002 was \$5 million, 12.7% of total revenue, and long-term assets outside the United States of America, net were \$5.2 million, 25.9% of total long-term assets, net.

Liquidity

To date, the Company has yet to achieve profitability. The Company does not expect to be profitable in 2003. The Company has implemented initiatives to increase sales and decrease expenses to assure its viability for the next 12 months. The Company also has developed a contingency plan in anticipation of prolonged negative business impact resulting from the War in Iraq.

To date, the Company's principal sources of liquidity have been proceeds from issuance of common stock and debt. At December 28, 2002. the Company had \$3.5

million in cash and borrowing capacity under lines of credit totaling \$300,000.

Additionally, as discussed below, subsequent to December 28, 2002, the Company obtained the following borrowing availability:

F-10

- o \$500,000 convertible notes under the same terms as the November 2002 Notes described in Note 9.
- o \$1.5 million increase in the Credit Agreements with CAP Advisers. The increase is for international revenue generating initiatives.
- o \$2.5 million Center Loan with CAP Advisers, as described below.

In April 2003, the Company obtained a commitment from CAP Advisers for a \$2.5 million Center Loan (the "2003 Center Loan") to be used for capital expenditures and other specific revenue generating initiatives to be agreed and defined by BriteSmile and Cap Advisers and up to \$800,000 for general working capital. Interest is fixed at 6%, payable monthly, with Cap Advisers having the right to reset the interest rate to 200bps over 1 year LIBOR after giving BriteSmile 30 days notice. A variable fee payment of \$25 per procedure performed on the existing 127 Center chairs will commence on May 11, 2006, and continue until May 10, 2011. Variable fees will be payable 40 days after the end of the month in which the procedures are performed, except for fees due for April/May 2011, which will become payable on the maturity date. On an annualized basis the first \$500,000 of variable fees will be applied to the principal such that the \$2.5M will be fully repaid over 5 years commencing May 11, 2006. Variable payments in excess of the annual amortization of \$500,000 are deemed additional interest to Cap Advisers.

The Company believes that cash on hand along with available borrowing capacity discussed above will be sufficient to sustain operations through the end of 2003.

2. Summary of Significant Accounting Policies

Year-End

In 2000, the Company changed its fiscal year-end to a 52/53-week period ending on the last Saturday in December of each year. Consequently, the accompanying financial statements reflect the audited financial position and results of operations of the Company for the 52 weeks ended December 28, 2002 and December 29, 2001, and the 39 weeks ended December 30, 2000.

Stock Split

Effective January 27, 2003, the Company's shareholders approved a 15 to 1 reverse stock split. All share and per share amounts in the accompanying consolidated financial statements have been restated to reflect the reverse stock split.

Consolidation

The accompanying consolidated financial statements include the accounts of the Company, its subsidiaries, and entities (Centers) in which the Company has a controlling interest. The Company consolidates the Centers for financial reporting because the Company has a controlling financial interest in the Centers. The agreements with the Centers are 30 year, non-terminable agreements that provide the Company a financial interest in the PPM (Physician Practice

Management Entities) and exclusive authority over all decision-making other than the dispensing of medical services. All inter-company balances and transactions have been eliminated upon consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

F - 11

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents are recorded at cost at the date of purchase, which approximates fair value.

Cash and Short-Term Investments, Restricted as to Use

At December 28, 2002 and December 29, 2001, \$843,000 of the Company's cash and short-term investments was used to collateralize letters of credit and is restricted as to use until September 2008.

Concentrations of Credit Risk

Credit Risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk consist principally of cash, cash equivalents and trade accounts receivable.

The Company maintains cash and cash equivalents with various financial institutions. These financial institutions are located throughout the United States of America and the Republic of Ireland. The Company's policy is designed to limit exposure to any one institution. The Company has not experienced any significant losses on its cash and cash equivalents. The Company performs periodic evaluations of the relative credit standing of those financial institutions that are considered in the Company's investment strategy. The Company does not require collateral on these financial instruments.

Concentration of credit risk with respect to trade accounts receivable are limited due to the large number of entities comprising the Company's customer base. No one customer accounted for 10% or more of revenue during any of the fiscal years covered in this report.

The Company performs ongoing credit evaluations of its associated centers and generally does not require collateral.

Supply Risk

Goods purchased to produce the LATW system and equip the Centers and Associated Centers are in some cases unique and purchased from a single vendor. In those

cases the Company believes it could purchase items meeting its design specifications from other vendors within the industry. Overall, the Company believes it has access to sufficient quantities of goods and materials at competitive prices to enable it to operate effectively.

Revenue Recognition

The Company recognizes revenue related to retail products at the time such products are sold to customers.

The Company recognizes revenue from teeth whitening procedures performed at its Centers and Associated Centers when the procedures have been performed. The Company defers the revenue generated on the sale of key cards and activation codes to Associated Centers and recognizes the income over the estimated performance period, which the Company has calculated to be 30 days. Revenue is reported net of discounts and allowances. Additionally, Associated Center revenue for the year ended December 28, 2002, December 29, 2001 and the Transition Period, has been reduced by \$163,000, \$163,000 and 122,000, respectively, due to charges related to warrants issued to Orthodontic Centers of America ("OCA").

F-12

Inventories

Inventories are stated at the lower of cost (first-in, first-out) or market. Inventories at December 28, 2002 and December 29, 2001 consist primarily of dental supplies, marketing materials and displays and replacement component parts for the teeth whitening systems, as follows:

	December 28, 2002	December 29, 2001
Supplies Marketing displays	\$ 2,240 262	\$ 1,765 775
Total Inventory	\$ 2,502	\$ 2,540

Other Assets

During 1999, the Company granted warrants to OCA in consideration of OCA installing BS3000 machines in OCA centers. The value of the warrants was capitalized and is being amortized as a reduction of revenue over the life of the agreement (10 years). Other assets were \$1.1 million and \$1.2 million at December 28, 2002 and December 29, 2001, respectively, representing the unamortized cost of the warrants.

Capital Leases

The Company leases certain equipment from a related party (see notes 5 and 7). Under the terms of these leases, the Company pays (i) a fixed monthly payment of principal and interest of \$75,000 per month and (iii) variable rent payments equal to \$25 per LATW procedure. The variable rent payments are recorded as an operating cost.

Advertising

Costs of advertising are expensed the first time the advertising takes place. Advertising costs were \$17.1 million, \$19.1 million and \$16.3 million for the 52 weeks ended December 28, 2002 and December 29, 2001, and the 39 weeks ended December 30, 2000, respectively, and are included in "Selling, general and administrative expenses" in the accompanying consolidated statements of operations.

Property and Equipment

Property and equipment is stated at cost, or in the case of property and equipment under capital lease, at fair market value, at the date of inception. Expenditures for maintenance and repairs are charged to expense as incurred, and expenditures for additions and betterments are capitalized. Furniture and fixtures and equipment are depreciated for financial reporting purposes over their estimated useful lives, ranging from three to ten years, using the straight-line method. Leasehold improvements are amortized for financial reporting purposes using the straight-line method over the shorter of the estimated useful life of the asset or the remaining term of the lease. Amortization expense related to assets under capitalized lease obligations is included in depreciation.

Stock-Based Compensation

The Company accounts for employee stock options using the intrinsic value method in accordance with Accounting Principles Board Opinion No. 25. Compensation expense based on the difference, if any, on the date of grant, between the estimated fair value of the Company's stock and the exercise price of options to purchase that stock is amortized over the vesting period of the related option.

The alternative fair value accounting provided for under Financial Accounting Standards Board Statement No. 123, "Accounting for Stock-Based Compensation" ("FAS 123"), requires use of option valuation models that were not developed for use in valuing employee stock options. Under APB 25, when the exercise price of

F-13

the Company's employee stock options equals the market price of the underlying stock on the date of grant, no compensation expense is recognized.

The fair value of the Company's options was estimated at the date of grant using a Black-Scholes option pricing valuation model with the following weighted-average assumptions: volatility of 1.09, 1.13 and 1.31 for the 52 weeks ended December 28, 2002, the 52 weeks ended December 29, 2001 and the 39 weeks ended December 30, 2000, respectively; an average risk-free interest rate of 4.25%, 4.75% and 5.72% for the 52 weeks ended December 28, 2002, for the 52 weeks ended December 29, 2001 and the 39 weeks ended December 30, 2000, respectively; dividend yield of 0%; and a weighted-average expected life of the option of 10 years.

Option valuation models were developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected life of the option. Because the Company's employee stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

Had compensation cost for the Company's stock-based compensation plans been determined using fair value at the grant award dates using the Black-Scholes option pricing valuation model, the Company's reported net loss applicable to common shareholders and basic and diluted net loss per share would have been increased to the pro forma amounts indicated below (in thousands, except per share data):

	52 Weeks Ended December 28, 2002	52 Weeks Ended D 29, 2001
Loss as reported	\$ 19 , 078	\$ 26,499
Compensation expense reported under APB25	\$ (265)	\$ -
Compensation expense computed using fair value method	\$ 3,562	\$ 2,595
Pro forma loss	\$ 22,375	\$ 29,094
Pro forma basic and diluted loss per share	\$ 9.22	\$ 13.01

Product Development Cost

Costs associated with the development of new products or services are charged to operations as incurred. These costs are included in "Research and development expenses" in the accompanying consolidated statements of operations.

Shipping and Handling Costs

Shipping and handling charges billed to customers are recorded in revenue and the related expenses are classified in operating and occupancy costs.

Center Opening Costs

 ${\tt Non-capital\ expenditures\ incurred\ in\ opening\ a\ new\ BriteSmile\ Professional\ Teeth}$ Whitening Center are expensed as incurred.

F - 14

Income Taxes

The Company uses the liability method of accounting for income taxes pursuant to Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes." Under the liability method, deferred tax assets and liabilities are provided on differences between the financial reporting and taxable loss, using the enacted tax rates.

Impairment of Long-Lived Assets

The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not

be recoverable. The Company does not perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company measures fair value based on quoted market prices or based on discounted estimates of future cash flows. Long-lived assets to be disposed of are carried at fair value less costs to sell.

Fair Value of Financial Instruments

The following methods and assumptions were used by the Company in establishing its fair value disclosures for financial instruments:

Cash and cash equivalents: The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value.

Accounts receivable, accounts payable, and accrued liabilities: The carrying amount reported in the balance sheet for accounts receivable, accounts payable, accrued liabilities and other current liabilities approximates its fair value.

Long and short-term debt: The carrying amounts of the Company's borrowings under its short-term revolving credit arrangements approximate their fair value. The fair values of the Company's long-term debt are estimated using discounted cash flow analyses, based on the Company's current incremental borrowing rates for similar types of borrowing arrangements. The carrying amounts of the Company's long-term debt approximate their fair value.

Loss Per Common Share

Basic net loss per share is calculated as net loss divided by the weighted-average number of common shares outstanding. For all periods presented, diluted net loss per share is equal to basic net loss per share. Common equivalent shares from stock options and warrants (using the treasury stock method) and convertible notes payable is anti-dilutive.

Recent Accounting Pronouncements

In August 2001, the FASB issued Statement of Financial Accounting Standards No. 144, "Accounting for the Impairment or Disposal of Long-lived Assets" ("SFAS 144"). SFAS 144 amends existing accounting guidance on asset impairment and provides a single accounting model for long-lived assets to be disposed of. Among other provisions, the new rules change the criteria for classifying an asset as held-for-sale. The standard also broadens the scope of businesses to be disposed of that qualify for reporting as discontinued operations, and changes the timing of recognizing losses on such operations. The Company adopted this

F-15

statement at the beginning of 2002 and adoption did not have a material impact on its consolidated financial statements.

In June 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities, which addresses accounting for restructuring and similar costs. SFAS 146 supersedes previous accounting guidance, principally Emerging Issues Task Force Issue No. 94-3. The Company will adopt the provisions of SFAS 146 for restructuring activities initiated after December 28, 2002. SFAS

146 requires that the liability for costs associated with an exit or disposal activity be recognized when the liability is incurred. Under Issue 94-3, a liability for an exit cost was recognized at the date of the Company's commitment to an exit plan. SFAS 146 also establishes that the liability should initially be measured and recorded at fair value. Accordingly, SFAS 146 may affect the timing of recognizing future restructuring costs as well as the amounts recognized.

Reclassifications

Certain prior year balances have been reclassified to conform to the current year presentation.

3. Change in Accounting Principle

During the last quarter of the Transition Period ended December 30, 2000, and retroactive to April 1, 2000, the Company has changed its method of accounting to recognize revenue from Associated Centers ratably over the estimated period in which the Associated Centers perform the procedures, commencing when the key card is shipped or the activation code is provided. Previously, the Company recognized revenues from Associated Centers when the keycard to activate the machine was shipped or the activation code is provided. The effect of the change of implementing SAB 101 for the Transition Period ended December 30, 2000 was to record a loss of \$272,000 (\$0.17 per share) as a cumulative effect of a change in accounting principle. The \$272,000, which represented deferred revenue at April 2, 2000, was recognized as revenue during the 39 weeks ended December 30, 2000. The pro forma effect of adopting SAB 101 was an increase in net loss of \$272,000 (\$0.17 per share) for the 39 weeks ended December 30, 2000.

4. Restructuring and Impairment Charges

During the 52 weeks ended December 28, 2002, the Company recorded additional \$304,000 charge related to leases obligations..

During the 52 weeks ended December 29, 2001, the Company decided not to continue the construction of a Center in San Francisco, California. As a result of this decision, the Company recorded a non-cash impairment charge of \$1.2 million related to leasehold improvements to be abandoned, whose fair value, based on estimates of recovery on sub-leases, was determined to be \$0. The Company also recorded an accrual to reserve for an estimated \$934,000 related to the remaining lease obligation for closed stores.

During the 39 weeks ended December 30, 2000, the Company's Board of Directors and management decided to close three of its less productive Centers. These Centers were located in Pasadena, California, Ft. Lauderdale, Florida, and Coral Gables, Florida. As a result of the decision to close these locations, the Company recorded a non-cash impairment charge of \$1.3 million related to leasehold improvements to be abandoned, whose fair value, based on estimates of recovery on sub-leases, was determined to be \$0. The Company also recorded an accrual of \$161,000 related to severance costs for 12 employees, and an accrual of \$617,000 related to lease termination costs for the closed Centers.

F - 16

The following table sets forth the restructuring activity during the years ended (in thousands):

	Accrual fo Store Closu at December 2001		ucturing arges	Cash Paid		Accrual Store Clo at Decemb 2002	
Restructuring expense Revision of December 29, 2001 estimate	\$	1,210	\$ - 304	\$	(278) -	\$	
Total	 \$ ======	1,210	\$ 304	\$ =====	(278)	\$ ======	
	Clos	for Store sures at er 30, 2000	ucturing arges 	Cas	sh Paid	Accrual fo Closures December 2	
Restructuring expense	\$	617	\$ 934	\$	(286)	\$	
Severance Revision of December 30, 2000 estimate		161	- (55)		(161)		
Total	\$	778	\$ 879	\$	(447)	 \$	

Impairment charges

5. Sale/Leaseback Transaction

Effective December 29, 2000, as amended in February 2001, the Company secured a lease line of up to \$15 million from Excimer Vision Leasing L.P. ("EVL"), a related party. Under this agreement, the Company entered into a sale-leaseback arrangement. During the period ended December 30, 2000, the Company sold 1,245 of its BS3000PB whitening devices for \$5 million and leased them back for a period of 5 years. The leaseback has been accounted for as a capital lease. A loss of \$7.1 million on this transaction has been recognized in the period ended December 30, 2000 as the fair market value of the equipment sold was less than its carrying value. The decline in fair value was the result of a decision to change to a new model of machine and to outsourcing the manufacturing, which contributed to a significant decline in the cost to purchase new machines. The Company will pay EVL a monthly rental for each device consisting of a fixed amount (ranging from twenty dollars to thirty dollars) plus one hundred twenty-five dollars for each key card.

The agreement further provided that EVL would spend up to an additional \$10 million towards the purchase of 1,755 BS3000PB devices to be leased to the Company under the same terms described above. To the extent the purchase price of the additional 1,755 devices exceeded \$10 million, the Company was obligated to pay the difference. As of December 29, 2001, the Company had fully utilized

the lease line made available by EVL.

F - 17

On March 8, 2002, the Company and EVL amended their lease agreement to provide that the variable rent portion of the monthly rental payments due during 2002, in the amount of twenty-five dollars for each BriteSmile procedure, will be deferred and paid to EVL in twelve equal monthly installments beginning January 9, 2003, with interest payable on the deferred amount (\$2.1 million at December 28, 2002) at a rate equal to LIBOR as quoted by The Bank of Nova Scotia for the applicable adjustment dates for deposits in U.S. Dollars for one month maturities, plus 200 basis points.

On January 1, 2003, the Company and EVL amended their lease agreement to provide that the variable rent portion of the monthly rental payments due for 2002 and 2003 be deferred until January 1, 2004. In addition, interest payable on the deferred amount, due on the 9th of each month, is calculated at a rate equal to LIBOR as quoted by The Bank of Nova Scotia for the applicable adjustment dates for deposits in U.S. Dollars for one month maturities, plus 200 basis points.

6. Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	December 28, 2002	December 29, 2001
Accrued salaries and benefits	\$ 840	\$ 1,183
Accrued professional services	728	369
Accrued advertising	1,064	930
Other accrued expenses	1,771	2,477
Total	\$ 4,403	\$ 4,959
	==-====	=======

7. Leases

The Company leases certain equipment under capital leases. The leases for equipment require the payment of certain fixed payments and contingent variable rentals based on usage. Payments related to variable rent were \$2,150,000, \$2,680,000, and \$0 for the 52 weeks ended December 28, 2002 and December 29, 2001 and the 39 weeks ended December 30, 2000, respectively.

The cost of assets under capital lease obligations was \$3.6million at December 28, 2002 and December 29, 2001. Accumulated amortization related to assets under capital lease obligations at December 28, 2002 and December 29, 2001 was \$1.2 million and \$516,000.

The Company recorded amortization expense of \$717,000, \$516,000, and \$0 under capital leases for the 52 weeks ended December 28, 2002, 52 weeks ended December 29, 2001 and the 39 weeks ended December 30, 2000, respectively.

The Company also leases office and retail space under non-cancelable operating leases with initial terms of five to ten years, including various renewal options and escalation clauses. Future minimum payments under capital leases and non-cancelable operating leases with initial terms of one year or more consisted

of the following at December 28, 2002 (in thousands):

	Capital Leases	Operating Leases
2003 2004 2005	\$ 956 900 900	\$2,921 2,523 1,974
F-18		
2006 2007 Thereafter	230	1,786 1,456 2,261
Total minimum lease payments	2 , 986	\$12,921
Amount representing interest	400	======
Present value of net minimum lease payments Less current portion	2,586 (701)	
Long-term capital lease obligation	 ns \$1,885 ======	

Rent expense was \$3.3 million, \$3.7 million and \$2.6 million for the 52 weeks ended December 28, 2002 and December 29, 2001, and the 39 weeks ended December 30, 2000, respectively.

8. Income Taxes

The Company accounts for income taxes using the asset and liability method under SFAS No. 109, "Accounting for Income Taxes". The Company provides a deferred tax expense or benefit for differences between financial accounting and tax reporting. Deferred income taxes represent future net effects of temporary differences between the financial statement and tax basis of assets and liabilities, using enacted tax rates in effect for the year in which the differences are expected to reverse.

The income tax expense (benefit) consisted of (in thousands):

	end Decemb	veeks ded oer 28, 002	e Dece	weeks nded mber 29, 2001	Decemb	eeks ded ber 30,
Current:						
Federal State	\$	80	\$	- 57	\$	- 26
Total current		80		57		26
Deferred: Federal	\$	-	\$	_	\$	_

	=====		=====		=====	
Total current and deferred	\$	80	\$	57	\$	26
Total deferred		_		_		_
beace						
State		_		_		_

F-19

Significant components of the Company's deferred tax balances at December 28, 2002 are as follows (in thousands):

Current deferred tax assets:	December 28, 2002	December 2001
Reserves and accruals Other, net	\$ 1,432 916	\$
Current deferred tax asset	2,348	1,
Long-term deferred tax asset Net operating loss carryforwards Property and equipment Tax credit carryforwards	45,632 1,343 441	38, 2,
Long-term deferred income tax assets	47,416	41,
Total deferred income tax asset	49,764	42,
Valuation allowance	(49,764)	(42,
Net deferred tax assets	\$ -	\$ =======

A reconciliation of the federal statutory tax rate to our effective state rate is as follows:

	52 Weeks ended December 28,	52 Weeks ended December 29,
Provision at statutory tax rate	2002 -34.00%	2001

De

	=======	=======
Total	0.17%	0.22%
Valuation allowance	40.11%	47.26%
Rates	-2.21%	-
Tax on foreign earnings at less than U.S.		
Non-deductible items	0.17%	-7.04%
of Federal benefit	-3.90%	-6.00%
State income tax benefits, net		

A valuation allowance is provided when it is more likely than not that some portion of the deferred tax asset will not be realized. The Company established a valuation allowance at December 28, 2002 due to the uncertainty of realizing tax benefits from certain of its net operating loss ("NOL") carryforwards and credits.

As of December 28, 2002, the Company had federal and state net operating loss carryforwards of approximately \$117.4 million and \$93.4 million, respectively. These net operating loss carryforwards will expire in years 2010 through 2022 for federal income tax expense purposes and years 2004 through 2012 for state income tax purposes. Additionally, the Company has approximately \$660,000 of net operating losses from the Republic of Ireland that may be carried forward indefinitely. A portion of the federal and state losses is attributable to professional corporations formed to comply with the corporate practice of medicine statutes in the jurisdictions where the Company has operations. These professional corporations are not consolidated for income tax purposes. Net operating loss carryforwards may be limited in the event of a change in control.

The Company has approximately \$378,000 of tax credits that under current tax law can be used to offset future income tax liabilities. These credits will begin to expire in 2005 if not utilized.

F-20

9. Financing Arrangements

Following is a summary of the Company's long and short-term debt financing arrangements (in thousands):

	December 28, 2002	December 29, 2001
Note Payable to EVL, a related party,		
due May 10, 2006 Line of credit 2% Convertible Promissory Note EVL variable rent 5% Subordinated Convertible Notes (net of discount of \$51 and \$71)	\$ 1,583 4,714 3,500 2,150	\$ 2,083 - - - 729
	\$ 12,696	\$ 2,812

The following table presents the approximate annual maturities of debt, net of discounts, for the 52 weeks ended December (in thousands):

2003	\$	500
2004		2,650
2005		4,749
2006		4,797
Total	\$	12,696
	=====	

On June 29 and August 3, 2000, the Company sold to eleven investors (the "Investors"), in a private placement, its 5% Subordinated Convertible Notes due June 29, 2005 (the "August 2000 Notes") in the aggregate principal amount \$20 million.

Initially, the August 2000 Notes were convertible into shares of the Company's common stock at a per share conversion price of \$92.70. The Company also issued to the Investors, pro rata, warrants (the "Warrants") to purchase a total of 107,875 shares of common stock, which have a term of five years and initially had an exercise price of \$108.15 per share. The fair value of the warrants issued of \$2.1 million was recorded as a discount of the August 2000 Notes and was being amortized over the life of the notes to interest expense. Seven of the Investors, who purchased an aggregate amount of \$15.7 million of the August 2000 Notes, are affiliates of the Company.

On December 5, 2000, the Company sold to LCO Investments Ltd in a private placement a Convertible Promissory Note (the "December 2000 Note") in the aggregate principal amount of \$5 million. In conjunction with the issuance of the December 2000 Note, warrants to purchase 16,667 shares of common stock were issued at an exercise price of \$75.00 per share. The warrants have a contractual life of 5 years and remain outstanding and unexercised. The fair value of the warrants issued of \$253,000 was recorded as a discount of the December 2000 Note and was being amortized over the life of the note to interest expense. The December 2000 Note was convertible into shares of common stock of the Company at a conversion price of \$75.00 per share. On April 10, 2001, LCO Investments Ltd. converted its Promissory Note in the original principal amount of \$5 million, together with accrued interest of \$132,644, into 68,435 shares of restricted common stock. The unamortized fair value of the warrants was recorded as interest expense upon conversion of the Note.

As a result of the issuance of the December 2000 Note, the conversion price of the August 2000 Notes, and the exercise price of the warrants, was automatically adjusted to \$75.00 per share. Additionally, the fair value of the Warrants was

F-21

adjusted to \$2.3 million based upon the change in conversion price and the discount of the August 2000 Notes was adjusted accordingly. The new fair value of the warrants was amortized on a straight-line basis over the life of the notes to interest expense.

In December 2000, two investors converted \$5.6 million of their original August 2000 Notes, together with accrued interest, into an aggregate of 74,822 shares of common stock. This conversion was effected at the \$75.00 conversion price.

Effective December 14, 2000, certain of the other original Investors agreed with

the Company to convert an aggregate of \$13.6 million in principal amount of their August 2000 Notes, together with interest, into 237,904 shares of common stock at an amended conversion price of \$57.938 per share.

Upon conversion of the notes, the related unamortized discount of \$2.2 million arising from the fair value of the Warrants was recorded as interest expense.

The Company also recorded \$314,000 of additional interest expense related to the \$75.00 per share beneficial conversion rate offered the Investors, and \$3.1 million of additional interest expense related to the \$57.938 per share inducement to convert offered to Investors as noted above. The amounts represent the difference between the stated conversion rates of the August 2000 Notes and the effective conversion rates considering the relative fair value attributed to the notes and the related warrants.

As of December 28, 2002, \$800,000 of the original August 2000 Notes remain outstanding. As a result of the issuance of the November 2002 Notes described below, the conversion price of these original August 2000 Notes, and the exercise price of the Warrants, was automatically adjusted to \$6.00 per share. The unamortized discount on these notes is \$51,000 as of December 28, 2002 and is being amortized over the life of the notes to interest expense. As a result of the change in the exercise price of the warrants, the Company recorded a deemed dividend of \$307,000 representing the change in the value of warrants.

Of the original Warrants issued in the August 2000 Note Offering, 100,421 Warrants remain outstanding and unexercised.

The conversion price of the remaining August 2000 Notes, and the exercise price of the outstanding Warrants, continues to be subject to additional adjustments from time to time upon the occurrence of certain other events described in the August 2000 Notes and Warrants, including future issuances of Common Stock for consideration less than the conversion price then in effect, stock splits or reverse stock splits, and the occurrence of certain major corporate events such as mergers, sale of assets, tender offers or exchange offers.

At any time after August 2003, the holders of the August 2000 Notes have the right, but not the obligation, to elect to cause the Company to redeem all or a portion of their August 2000 Notes.

Effective March 1, 2001, the Company borrowed \$2.5 million from EVL for general working capital. The loan matures on May 10, 2006. In October 2001, this loan was amended to allow for early prepayments without penalty. Payments under the loan consist of "fixed payments" of interest, "variable payments" of principal, and a "final payment" of principal. An initial fixed payment of \$10,417 was paid on April 1, 2001. Additional monthly payments of \$12,500 are due during the loan period. Variable payments are twenty-five dollars for each BriteSmile teeth whitening procedure performed at the Company's 14 whitening Centers. Variable payments totaled \$717,000 and \$664,000 for the year ended December 28, 2002 and December 29, 2001, respectively. The final payment, due at maturity, will be the amount by which the aggregate of variable payments paid during the term of the loan is less than the original \$2.5 million principal amount of the loan.

F-22

In December 2001, as amended in March 2002, July 2002 and January 2003 BriteSmile International entered into Credit and Security Agreements (the "Credit Agreements") with CAP Advisers Limited ("CAP Advisers"). The Credit Agreements provide for secured loans to the Company of up to \$5 million with an

additional \$1.5 million for capital equipment. Any principal advanced under the line of credit bears interest at a fluctuating rate equal to LIBOR plus 200 basis points, payable monthly. Advances under the \$5 million line may be used for general business purposes. The line of credit expires in December 2006. As of December 28, 2002, the Company had \$4.7 million outstanding on the line of credit. Mr. Pilaro, the Company's Chairman, is also Chairman of CAP Advisers. CAP Advisers is the sole trustee of the ERSE Trust. The ERSE Trust owns 100% of LCO, the Company's major shareholder.

On November 20, 2002, the Company sold to two investors in a private placement 2% convertible notes that are due and payable on November 20, 2005 (the "November 2002 Notes"). The November 2002 Notes are convertible into shares of common stock of the Company at a conversion rate of \$6.00 per share. The two investors who purchased the November 2002 Notes, both affiliates of the Company, are: LCO Investments Limited (\$2,500,000) and Bradford G. Peters (\$1,000,000). The CEO of the Company has agreed to fund an additional \$500,000 in 2003 under the same terms.

10. Shareholder's Equity

On April 30, 2001, the Company completed a private offering (the "Offering") of its restricted common stock, par value \$0.001 per share ("common stock"). The Offering involved sales of a total of 358,095 shares of restricted common stock to 17 accredited investors and their affiliated funds (the "Investors"). None of the Investors was affiliated with the Company before the completion of the Offering. The Company sold the shares of common stock issued in connection with the Offering for \$78.75 per share, yielding net proceeds to the Company of \$26.6 million.

In connection with the Offering, the Company engaged Stonegate Securities, Inc., Dallas, Texas (the "Placement Agent"), to act as placement agent for the Offering. For its services, the Company agreed to pay the Placement Agent five percent of the gross proceeds of the Offering, or \$1.4 million and issue to the Placement Agent warrants to purchase a total of 35,809 shares of restricted common stock for a per share purchase price of \$78.75. The warrants have a five-year term.

In connection with the Offering, on March 14, 2001, the Company issued warrants to purchase 6,667 shares of common stock for a per share price of \$75.00 to Pequot Partners Fund, L.P., Pequot Private Equity Fund II, L.P., Pequot International Fund, Inc., LCO Investment Limited, P de P Tech Limited, John Reed and Brad Peters, in exchange for agreeing to cover any cash shortfall in the Offering up to \$5 million. The warrants have a five-year term. The fair value of the warrants of \$225,000 was netted against the Offering proceeds.

Stock Option Plans

In January 1997, the Company adopted the 1997 Stock Option and Incentive Plan ("1997 Plan"). Under the terms of the 1997 Plan, as amended to date, and as approved by the Company's shareholders, 500,000 shares are available for issuance. Options may be granted at exercise prices of no less than the fair market value on the date of the grant, as determined by the Board of Directors and quoted market prices. Options generally vest over a five-year period and have a maximum term of ten years.

A summary of the Company's stock option activity and related information for the 52 weeks ended December 28, 2002, the 52 weeks ended December 29, 2001 and the 39 weeks ended December 30, 2000 is as follows:

	52 weeks ended December 28, 2002			52 weeks ended December 29, 2001		
	Options	Weighted- Average Exercise Price Per Share	Options	Weighted- Average Exercise Price Per Share	 Options	
Outstanding at beginning						
Of year	405,768	\$78.30	424,728	\$82.50	409,512	
Granted	125,712	62.88	90,183	79.01	77,200	
Exercised	(13,333)	29.49	(30,736)	43.06	(10,917)	
Forfeited/expired	(200, 478)	96.04	(78,407)	93.13	(51,067)	
Outstanding at end of year	317,669	75.90	405,768	78.30	424 , 728	
_			=======		=======	

Exercise prices for outstanding options as of December 28, 2002 ranged from \$4.95 to \$206.25 per share and the weighted-average remaining contractual life of those options outstanding at December 28, 2002 and December 29, 2001 was 8.39 years and 6.30 years, respectively. The weighted average fair market value of options granted during the 52 weeks ended December 28, 2002 and the 52 weeks ended December 29, 2001 and the 39 weeks ended December 30, 2000 was \$57.90, \$79.05, and \$88.95, respectively.

A summary of the status of options outstanding at December 28, 2002 is as follows:

Outstanding Options

Exercisable Options

Range of Exercise Price Per Share		Weighted Average Remaining Contractual Life (in Years)	Weighted Average Exercise Price Per Share	
\$4.95 - 12.75	14,800	10.00	5.76	6 , 667
15.00 - 28.80	54,400	8.10	22.06	51,133
31.20 - 44.10	78,356	8.87	38.21	58,556
45.00 - 58.50	75 , 822	9.19	57.55	20,922
61.95 - 74.10	27,757	8.26	68.10	17,702
75.00 - 106.95	27,312	8.58	84.56	23,546
120.00-206.25	39,222	8.37	152.16	36,689
Total	317,669			215,215
	======			======

Shares Reserved for Future Issuance

The Company has reserved shares of common stock for future issuance as follows:

	December 28, 2002
Employee stock options outstanding	296,269
Non-employee stock options outstanding	21,400
Stock options, available for grant	182,331
Warrants outstanding	144,794

Options/Warrants Granted Outside 1997 Plan

Options or warrants for 110,222 shares have been granted to certain vendors, consultants and employee outside the 1997 Plan. Of the shares granted, 47,733 remain outstanding and unexercised as of the date of

F-24

this Report. The weighted average exercise price of such outstanding $\,$ options or warrants is \$73.00 per share.

Acceleration of Employee Stock Options

In March 2002, options to purchase 2,667 shares of common stock were accelerated for two employees. As a result, the Company recognized, in selling, general and administrative expense, a non-cash expense of \$265,000.

Impact of Options/Warrants on Fiscal 2002 Financials Statement

In November 1998, the Company issued options to purchase 20,000 shares of common stock at \$17.8125 to Oral Health Clinical Services. Five thousand (5,000) options vested immediately and on October 31, 2001, another 5,000 options vested as a result of submission of clinical data to the American Dental Association (ADA), which resulted in a non cash expense of \$305,000. The balance of 10,000 shares vested in July 2002. As a result of the final 10,000 shares vesting in July 2002, the Company recognized a non-cash expense of \$217,000 during 2002.

Warrants

On September 21, 2001, the Company issued warrants to purchase 6,667 shares of the Company's common stock to Dr. Salim Nathoo and Dr. John Warner as compensation for consulting services to the Company for the period October 1, 2001 to December 31, 2002. During 2001, the Company recorded a non cash charge of \$154,000 related to these warrants. The warrants are exercisable at \$83.25 per share and expire September 21, 2003.

11. Net Loss Per Share of Common Stock

The calculation of basic and diluted net loss per share is as follows (in thousands, except share data):

52 Weeks Ended December 28, 2002 52 Weeks Decembe 2001

Net loss before cumulative effect of change in accounting

principle Cumulative effect of change in accounting principle Deemed dividend related to warrants	\$ (18,771) - 307	\$ (26
Net loss attributable to common shareholders	\$ (19,078)	\$ (26
Weighted-average shares of common stock outstanding used in computing basic and diluted net loss per share	2,427,412	2,236
Basic and diluted net loss per common share before cumulative effect of change in accounting principle	\$ (7.86)	\$ (1
Cumulative effect of change in accounting principle	\$ -	\$
Basic and diluted net loss per common share	\$ (7.86) ========	====== \$ (1 ======

F-25

12. Commitments and Contingencies

Litigation

BriteSmile, Inc. v. Discus Dental, Inc. and Salim Nathoo, filed in the United States District Court for the Northern District of California. The Company filed an initial complaint against Discus Dental, Inc. ("Discus"), Culver City, California, on July 8, 2002, asserting claims of infringement of the Company's U.S. Patents No. 6,343,933, issued February 5, 2002, and U.S. Patent No. 6,361,320, issued March 26, 2002. On February 28, 2003, the Company amended its existing lawsuit against Discus by adding Salim Nathoo ("Nathoo") as a defendant. The complaint, civil action number 3:C02-CV-03220 JSW, as amended, further alleges misappropriation of the Company's trade secrets, civil conspiracy, and unfair competition and business practices by Discuss and Nathoo; breach of contract and breach of fiduciary duty by Mr. Nathoo, and tortuous interference with contract by Discus. The complaint alleges that Nathoo and Discus conspired to misappropriate BriteSmile's trade secrets in violation of Nathoo's contractual obligations to the Company. The amended lawsuit alleges that, as BriteSmile's Medical Director, Nathoo had and continues to have, an obligation to keep BriteSmile's trade secrets confidential. Beginning in 2001, Discus Dental and Nathoo entered into an agreement whereby Discus Dental paid Nathoo at least \$2.5 million over a less than two year period for Nathoo's "consulting" services, which included paying Nathoo to share with Discus the Company's trade secrets. The lawsuit alleges further that in, December 2002, a third party informed BriteSmile of Nathoo's activities, and that when confronted by BriteSmile, Nathoo admitted to receiving \$2.5 million from Discus. The Company seeks a permanent injunction against both Discus and Nathoo to prevent further infringement of its patents and improper disclosure of the Company's trade secrets, lost profits, treble damages and attorneys fees for willful patent infringement, punitive damages, and other relief.

On March 25, 2003, Discus filed its Answer to the Amended Complaint and Counterclaims. In its Answer, Discus denies any liability for BriteSmile's claims. Discuss also raises affirmative defenses, including claims that its

products and processes do not infringe BriteSmile's patents, and that BriteSmile's patents are invalid and unenforceable. Discus asserts counterclaims against BriteSmile, seeking (i) judicial declarations that BriteSmile's patents are invalid, unenforceable, and have not been infringed, (ii) tortuous interference with prospective economic advantage and economic business relations, and (iii) unfair competition. Discus asks for declarations that its products and processes to not violate BriteSmile's patents, that BriteSmile's patents are unenforceable, that BriteSmile has no protectable trade secrets, that BriteSmile's contracts with dentists which contain contractual restrictions on the purchase and use of competitive systems are unenforceable and should be enjoined, lost profits, treble damages and attorneys fees.

Salim Nathoo v. BriteSmile Leasing. On March 6, 2003, Nathoo filed a lawsuit against BriteSmile Leasing, a subsidiary of the Company, in the New Jersey state court. In this action, Nathoo alleges that the Company breached its agreement to pay Nathoo money, and that such failure should result in the reversion of certain patent rights, which were previously assigned by Nathoo to the Company, back to Nathoo. As of March 31, 2003, counsel for the Company is preparing to answer to the amended complaint.

Smile Inc. Asia Pte. Ltd. v. BriteSmile. On April 23, 2002, Smile Inc. Asia Pte. Ltd. ("Smile") sued the Company and BriteSmile Management, Inc., a wholly owned subsidiary of the Company, in the Third Judicial District Court in Salt Lake City, Utah. The Complaint alleges that BriteSmile Management breached its 1998 distributor agreement with Smile by failing to fill orders placed and to perform other obligations under the agreement. The Complaint also alleges that BriteSmile Management and the Company fraudulently induced Smile to enter into the distributor agreement, and includes claims for damages based on alleged

F-26

unjust enrichment, civil conspiracy, breach of the duty of good faith and fair dealing, interference with contractual and economic relations, and fraudulent transfer. The Company believes that the claims asserted by Smile are entirely without merit and will vigorously defend the lawsuit. The Company has commenced discovery with regard to Smile's claims.

BriteSmile v. Discus Dental, filed in Contra Costa County Superior Court, California. On May 31, 2002, the Company filed a complaint against Discus Dental, Inc. in Contra Costa County Superior Court, California, case no. C02-01611, alleging causes of action for Intentional Interference with Contractual Relationship, Negligent Interference with Contractual Relationship, Violation of Unfair Business Practice Act - Loss Leader, Violation of Unfair Business Practice Act, Trade Libel and Injunctive Relief. The complaint alleges that Discus Dental and other defendants yet to be identified wrongfully interfered with the Company's contractual relationships with its Associated Center dentists, in part by writing letters with the purpose of inducing the Company's Associated Dentists to terminate their contracts with the Company and switch to Discus' Zoom! system, and by making false and disparaging statements concerning the Company's system. The Complaint seeks damages for loss of business, punitive damages, injunctive relief, and costs of suit. On June 27, 2002, Discus filed a demurrer to the Company's complaint, challenging the legal sufficiency of the complaint. On June 30, 2002, the court ruled that the Company will be able to pursue its claims as alleged in the complaint except for the second cause of action alleging Negligent Interference with Contractual Relationship. This case was stayed on March 11, 2003 and will remain stayed until a status conference scheduled for September 2003.

The Company is also subject to legal proceeding and claims in the ordinary course of business, including claims of alleged infringement of trademarks and other intellectual property rights.

The Company is not aware of any legal proceeding or claims that it believes will have individually or in the aggregate, a material adverse effect on its financial position or results of operations.

13. Related Party Transactions

November 2002 Sale of Convertible Notes

On November 20, 2002, the Company sold to two investors in a private placement 2% convertible notes that are due and payable on November 20, 2005 (the "November 2002 Notes") in a private placement. The November 2002 Notes are convertible into shares of common stock of the Company at a conversion rate of \$6.00 per share. The two investors who purchased the November 2002 Notes, both affiliates of the Company, are: LCO Investments Limited (\$2,500,000) and Bradford G. Peters (\$1,000,000). The CEO of the Company has agreed to fund an additional \$500,000 in 2003 under the same terms. LCO Investments Limited is the Company's major shareholder. LCO is a wholly owned subsidiary of the ERSE Trust. CAP Advisers Limited is a co-trustee of the ERSE Trust. Mr. Pilaro, a director of the Company, is Chairman of CAP. John L. Reed is a shareholder, the Chief Executive Officer, and a director of the Company. Brad Peters is a shareholder and a director of the Company.

LCO Properties Sublease

On December 1, 1999 the Company, as lessee, entered into an Agreement of Sublease with LCO Properties, Inc., a Delaware corporation, as lessor. LCO Properties, Inc. is affiliated with the Company's principal shareholder, LCO Investments Limited ("LCO"). The Sublease covers approximately 4,821 square feet of space located in New York City for a Center. The sublease term is for ten years and calls for initial lease payments of \$402,000 per year, subject to increase in the event of increases in the rent payable under the parent lease for the property between LCO Properties, Inc., and its lessor.

Public Relations Services Agreement

F-27

On April 7, 1999, the Company entered into a Letter Agreement with Chlopak, Leonard, Schechter and Associates ("CLS"), a public relations firm in Washington, D.C. Pursuant to the agreement, CLS provides public relations advice and serves as communications counselors to the Company for consideration of \$18,000 per month, plus expenses. The agreement was entered into for a minimum of six months, and remains in force. Peter Schechter, a director of the Company, is one of three managing partners of CLS.

Oral Health Clinical Services Agreement

On March 24, 1999, the Company entered into a Consulting Agreement with Oral Health Clinical Services, LLC, ("Oral Health") Salim A. Nathoo, and R. Eric Montgomery. Mr. Montgomery is a director of the Company. Pursuant to the agreement, Oral Health and Nathoo will devote their services to obtaining American Dental Association (ADA) Certification for the BriteSmile 2000 Tooth Whitening Procedure. The term of the contract is for two years or until ADA Certification, whichever is earlier. The Company issued options to purchase

20,000 shares of common stock at \$17.8125 to Oral Health Clinical Services. Five Thousand (5,000) options vested immediately and on October 31, 2001, another 5,000 options vested as a result of a submission of clinical data to the American Dental Association (ADA), which resulted in a non cash expense of \$305,000. The balance of 10,000 shares vested in July 2002. As a result of the final 10,000 shares vesting in July 2002, the Company recognized a non-cash expense of \$217,000 during 2002.

Oraceutical Agreement

On November 27, 2000, the Company entered into a Consulting Agreement with Oraceutical, LLC. R. Eric Montgomery, a director of the Company, is the founding Manager and President of Oraceutical. Pursuant to the agreement, Oraceutical provides technology development services to the Company for various light-activated teeth whitening products and procedures. In consideration for its services, Oraceutical, or its affiliates, have been paid \$25,000 a month, plus options to purchase 13,333 shares of common stock, which are fully vested and remain outstanding and unexercised, exercisable at \$56.25 per share.

EVL Lease Agreement

On December 29, 2000, as amended through January 2003, the Company secured a lease line of credit of up to \$15 million from Excimer Vision Leasing L.P. ("EVL"). Anthony Pilaro, the Company's Chairman, serves as Chairman of EVL. An affiliate of LCO Investments Inc., the Company's largest shareholder, owns 70% of EVL.

EVL Loan Agreement

On March 1, 2001, the Company borrowed \$2.5 million from EVL for general working capital. The loan matures on May 10, 2006 and may be prepaid at any time without penalty. Payments under the loan consist of "fixed payments" of interest, "variable payments" of principal and interest and a "final payment" of principal. An initial fixed payment of \$10,417 was paid on April 1, 2001. Additional fixed monthly payments of \$12,500 are due during the loan period. Variable payments are \$25 for each LATW procedure performed at the Company's 14 Centers. For Fiscal 2002, Fiscal 2001 and the Transition Period variable payments totaled \$717,000, \$664,000 and \$0, respectively, and the unpaid balance of the loan was \$1,583,000 at December 28, 2002. The final payment, due at maturity will be the amount by which the aggregate of variable payments paid during the term of the loan is less than the original \$2.5 million principal amount of the loan.

CAP Advisers Line of Credit

In December 2001, as amended in March, July 2002 and January 2003, BriteSmile International, a wholly-owned subsidiary of the Company, entered into Credit and Security Agreements with CAP Advisers which provide for a \$6.5 million line of credit facility of which \$1.5 million is for the purchase of capital equipment. As of December 28, 2002, \$4.7 million has been drawn on the line. LCO Investments Limited is the Company's major shareholder. LCO is a wholly owned

F-28

subsidiary of the ERSE Trust. CAP Advisers Limited is a co-trustee of the ERSE Trust. Mr. Pilaro, a director of the Company, is Chairman of CAP.

14. Benefit Plans

In March 2000, the Company adopted a 401(k) defined contribution plan covering substantially all employees. Employees become eligible to participate in the plan beginning the first month following their hire date. The plan contains provisions for an employer contribution at the discretion of management. To date, the Company has made no contributions to the plan.

F-29

15. Unaudited Quarterly Financial Data

F-30

The Company has included the following information below to demonstrate the effect on Q1 through Q4 of the 52 weeks ended December 28, 2002 and Q1 through Q4 of the 52 weeks ended December 29, 2001 (unaudited),:

		June 29, 2002	September 28, 2002	
Revenue Total operating costs and expenses Loss from operations	13,080	13,878	\$ 9,946 14,383 (4,437)	15 , 135
Net loss	\$ (4,132)	\$ (2,986)	\$ (4,603)	\$ (7,050
Basic and diluted net loss per share	\$ (1.65)	\$ (1.20)	\$ (1.95)	\$ (2.90
	·	June 30, 2001	-	
Revenue Total operating costs and expenses Loss from operations	14,792		\$ 13,359 17,444 (4,085)	19,936
Net loss	\$ (6,143)	\$ (5,473)	\$ (4,132)	\$(10 , 751
Basic and diluted net loss per share	\$ (3.15)	\$ (2.40)	\$ (1.80)	\$ (4.50

F-31

Financial Statement Schedule II

Schedule II--Valuation and Qualifying Accounts for the three fiscal periods ended December 28, 2002.

All other schedules are omitted as the required information is not applicable or the information is presented in the consolidated financial statements and notes thereto in Item 8 above.

Schedule II

BriteSmile, Inc. Valuation and Qualifying Accounts

	52 Weeks Ended December 28, 2002		52 Weeks Ended December 29, 2001	
Allowance for doubtful accounts - trade accounts receivable:			(in	thousands)
Balance, beginning of period Additions to allowance Write-offs, net of recoveries	\$	615 276 (385)	\$	163 676 (224)
Balance, end of period	\$ ======	506 ======	\$ = =======	615